<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Nucl Med Mol Imaging</journal-id><journal-id journal-id-type="iso-abbrev">Eur J Nucl Med Mol Imaging</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>European Journal of Nuclear Medicine and Molecular Imaging</journal-title></journal-title-group><issn pub-type="ppub">1619-7070</issn><issn pub-type="epub">1619-7089</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12119765</article-id><article-id pub-id-type="pmcid-ver">PMC12119765.1</article-id><article-id pub-id-type="pmcaid">12119765</article-id><article-id pub-id-type="pmcaiid">12119765</article-id><article-id pub-id-type="pmid">39909885</article-id><article-id pub-id-type="doi">10.1007/s00259-025-07116-2</article-id><article-id pub-id-type="publisher-id">7116</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Unveiling the potential of copper-61 vs. gallium-68 for SSTR PET imaging</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1924-178X</contrib-id><name name-style="western"><surname>Fonseca</surname><given-names initials="AI">A. I.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9607-6653</contrib-id><name name-style="western"><surname>Sereno</surname><given-names initials="J">J.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9018-2220</contrib-id><name name-style="western"><surname>Almeida</surname><given-names initials="S">S.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1658-9326</contrib-id><name name-style="western"><surname>Ferreira</surname><given-names initials="H">H.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1671-7861</contrib-id><name name-style="western"><surname>Hrynchak</surname><given-names initials="I">I.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3854-6549</contrib-id><name name-style="western"><surname>Falc&#227;o</surname><given-names initials="A">A.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8054-4267</contrib-id><name name-style="western"><surname>Alves</surname><given-names initials="F">F.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7497-4129</contrib-id><name name-style="western"><surname>Gomes</surname><given-names initials="C">C.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4145-854X</contrib-id><name name-style="western"><surname>Abrunhosa</surname><given-names initials="AJ">A. J.</given-names></name><address><email>antero@pet.uc.pt</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04z8k9a98</institution-id><institution-id institution-id-type="GRID">grid.8051.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9511 4342</institution-id><institution>ICNAS Pharma, </institution><institution>University of Coimbra, </institution></institution-wrap>Coimbra, Portugal </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04z8k9a98</institution-id><institution-id institution-id-type="GRID">grid.8051.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9511 4342</institution-id><institution>CIBIT/ICNAS, Institute for Nuclear Science Applied to Health, </institution><institution>University of Coimbra, </institution></institution-wrap>Coimbra, Portugal </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04z8k9a98</institution-id><institution-id institution-id-type="GRID">grid.8051.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9511 4342</institution-id><institution>Coimbra Institute for Clinical and Biomedical Research (iCBR), </institution><institution>Faculty of Medicine, University of Coimbra, </institution></institution-wrap>Coimbra, Portugal </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04z8k9a98</institution-id><institution-id institution-id-type="GRID">grid.8051.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9511 4342</institution-id><institution>Center for Innovative Biomedicine and Biotechnology Consortium (CIBB), </institution><institution>University of Coimbra, </institution></institution-wrap>Coimbra, Portugal </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04z8k9a98</institution-id><institution-id institution-id-type="GRID">grid.8051.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9511 4342</institution-id><institution>Faculty of Pharmacy, </institution><institution>University of Coimbra, </institution></institution-wrap>Coimbra, Portugal </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01n8x4993</institution-id><institution-id institution-id-type="GRID">grid.88832.39</institution-id><institution-id institution-id-type="ISNI">0000 0001 2289 6301</institution-id><institution>ESTeSC - Coimbra Health School, </institution><institution>Instituto Polit&#233;cnico Coimbra, </institution></institution-wrap>Coimbra, Portugal </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>52</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">489494</issue-id><fpage>2671</fpage><lpage>2684</lpage><history><date date-type="received"><day>5</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>24</day><month>1</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>30</day><month>05</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-05-30 04:25:16.627"><day>30</day><month>05</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="259_2025_Article_7116.pdf"/><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">In recent years, copper-61 has attracted considerable attention from both physicists and radiochemists due to its favorable physical decay properties for PET imaging and its ease of production at any cyclotron center producing [<sup>18</sup>F]FDG. The aim of this study was to evaluate the potential of <sup>61</sup>Cu-based radiopharmaceuticals for PET imaging of NETs, as an alternative to the commonly used gallium-68.</p></sec><sec><title>Methods</title><p id="Par2">Copper-61 was produced by irradiation of natural zinc liquid targets, followed by post-processing. In vitro evaluation of <sup>61</sup>Cu- and <sup>68</sup>Ga-labeled SST analogues was performed in SSTR positive AR42J tumor cells. PET/MRI was carried out in mice bearing AR42J subcutaneous tumors.</p></sec><sec><title>Results</title><p id="Par3">High molar activity [<sup>61</sup>Cu]Cu-DOTA-TATE and [<sup>61</sup>Cu]Cu-NOTA-TATE were successfully prepared with a radiochemical purity of over 95% and were shown to be stable for at least 6&#160;h after the EOS. Both <sup>61</sup>Cu- and <sup>68</sup>Ga-labeled SST analogues exhibited high cellular uptake, with residual uptake when blocked with an excessive amount of peptide precursor. [<sup>61</sup>Cu]Cu-NOTA-TATE showed the highest tumor uptake at 1&#160;h p.i. (13.25&#8201;&#177;&#8201;1.86%ID/g) and the tumor-to-non-tumor ratio increased from 1&#160;h to 4&#160;h p.i. At the later time point, tumor visualization improved compared to 1&#160;h p.i. Moreover, preclinical PET/MR images demonstrated that [<sup>61</sup>Cu]Cu-NOTA-TATE has a more favorable biodistribution and imaging properties than [<sup>61</sup>Cu]Cu-DOTA-TATE, with the extended PET imaging window providing a clear advantage of [<sup>61</sup>Cu]Cu-NOTA-TATE over its gallium-68 analogues.</p></sec><sec><title>Conclusion</title><p id="Par4">[<sup>61</sup>Cu]Cu-NOTA-TATE showed similar biodistribution and pharmacokinetics to [<sup>68</sup>Ga]Ga-DOTA-TATE at 1&#160;h p.i., while demonstrating superior imaging characteristics for late PET imaging. These findings demonstrate that [<sup>61</sup>Cu]Cu-NOTA-TATE holds promising characteristics for improving the detection of NETs with increased translational potential.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s00259-025-07116-2.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Copper-61</kwd><kwd>PET</kwd><kwd>DOTA-TATE</kwd><kwd>NOTA-TATE</kwd><kwd>NETs</kwd></kwd-group><funding-group><award-group><funding-source><institution>Universidade de Coimbra</institution></funding-source></award-group><open-access><p>Open access funding provided by FCT|FCCN (b-on).</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par5">Neuroendocrine tumors (NETs) are rare, heterogenous, and usually slow-growing malignancies that arise from the secretory cells of the neuroendocrine system, primarily in the gastrointestinal or respiratory organs. Nonetheless, they can be found in various tissues throughout the body and are classified according to their tissue of origin [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Most NETs are known to overexpress somatostatin receptor 2 (SSTR2) and other SSTR subtypes in variable extent based on their degree of differentiation [<xref ref-type="bibr" rid="CR3">3</xref>]. This makes these receptors highly specific targets for the diagnostic and therapeutic strategies in patients with NETs [<xref ref-type="bibr" rid="CR4">4</xref>]. In 1989, Krenning and co-workers imaged SSTR using a radioiodinated synthetic derivative of somatostatin (SST) - [<sup>123</sup>I]I-Tyr3-octreotide. The images were acquired using a gamma camera and revealed tumor localization in patients with various tumor types, all of which exhibited SSTR overexpression [<xref ref-type="bibr" rid="CR5">5</xref>]. After [<sup>123</sup>I]I-Tyr3-octreotide, Octreoscan<sup>&#174;</sup> ([<sup>111</sup>In]In-DTPA-dPhe-octreotide or [<sup>111</sup>In]-pentreotide) became the first radiopharmaceutical approved by regulatory agencies for the scintigraphy imaging of SSTR. Octreoscan<sup>&#174;</sup> showed high affinity for both SSTR2 and SSTR5 and became the golden standard for functional imaging of NETs [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Later, PET imaging with [<sup>68</sup>Ga]Ga-DOTA-peptides showed superiority in direct comparison with Octreoscan<sup>&#174;</sup> for metastasis detection, since they can detect a higher number of lesions, thereby displaying higher sensitivity [<xref ref-type="bibr" rid="CR8">8</xref>&#8211;<xref ref-type="bibr" rid="CR10">10</xref>]. Today, despite slight differences in their SSTR affinities, [<sup>68</sup>Ga]Ga-DOTA-TOC, [<sup>68</sup>Ga]Ga-DOTA-TATE and [<sup>68</sup>Ga]Ga-DOTA-NOC show no significant disparities in clinical practice and are currently the most routinely used radiopharmaceuticals in clinical applications [<xref ref-type="bibr" rid="CR11">11</xref>&#8211;<xref ref-type="bibr" rid="CR13">13</xref>]. The primary indication for these radiopharmaceuticals is PET imaging of SSTR overexpressed in well-differentiated NETs, including gastroenteropancreatic (GEP) NETs, pulmonary NETs, paraganglioma and meningioma. Once the expression of SSTR has been assessed, it will help to provide prognostic data and select patients for peptide receptor radionuclide therapy (PRRT) with [<sup>177</sup>Lu]Lu-DOTA-TATE.</p><p id="Par6">The first copper-based radiopharmaceutical incorporating a SSTR agonist was an octreotide (OC) conjugate labeled with copper-64 [<xref ref-type="bibr" rid="CR14">14</xref>]. Later, a head-to-head comparison of [<sup>64</sup>Cu]Cu-DOTA-TATE with Octreoscan<sup>&#174;</sup>, showed that [<sup>64</sup>Cu]Cu-DOTA-TATE performance far exceeded that of [<sup>111</sup>In]In-DTPA-dPhe-octreotide, while also demonstrating sufficient stability to be used as PET imaging agent [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. More recent clinical studies directly comparing [<sup>64</sup>Cu]Cu-DOTA-TATE with the PET standard [<sup>68</sup>Ga]Ga-DOTA-TOC [<xref ref-type="bibr" rid="CR17">17</xref>], demonstrated that more positive lesions were detected with [<sup>64</sup>Cu]Cu-DOTA-TATE than those with [<sup>68</sup>Ga]Ga-DOTA-TOC in patients with NETs. This difference was attributed to the lower positron energy range of copper-64 compared to gallium-68, rather than differences in the peptide itself. Further clinical studies evaluating [<sup>64</sup>Cu]Cu-DOTA-TATE, demonstrated high-quality imaging from 1 to 3&#160;h p.i., which along with the 12.7&#160;h half-life of copper-64, provide practical and logistical benefits by increasing the optimal timeframe for PET/CT scans in clinical routine of [<sup>64</sup>Cu]Cu-DOTA-TATE [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. A phase III prospective clinical trial confirmed the previously observed results with [<sup>64</sup>Cu]Cu-DOTA-TATE and determined that the copper-64 radiopharmaceutical was highly accurate in lesion detection, providing reproducible results [<xref ref-type="bibr" rid="CR20">20</xref>]. In sum, these studies indicate that the substitution of gallium-68 for copper-64 on these SST agonists-based radiopharmaceuticals has most likely a positive impact on their performance as PET radiopharmaceuticals. In this context, copper-61 emerges as a potential alternative to both gallium-68 and copper-64. Its half-life of 3.33&#160;h aligns better with the in vivo pharmacokinetics of peptide-based radiopharmaceuticals compared to copper-64, while demonstrating improved PET imaging characteristics in comparison to gallium-68 [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par7">We have previously reported on the feasibility of producing clinical amounts of <sup>61</sup>Cu-based radiopharmaceuticals, namely [<sup>61</sup>Cu]Cu-DOTA-TATE, [<sup>61</sup>Cu]Cu-DOTA-NOC, and [<sup>61</sup>Cu]Cu-DOTA-TOC, using a biomedical cyclotron and the cost-effectiveness of this method [<xref ref-type="bibr" rid="CR22">22</xref>]. Furthermore, the favorable physical properties of copper-61 compared to copper-64 (T<sub>1/2</sub> = 12.7&#160;h, 18% &#946;<sup>+</sup>, E<sub>max</sub> = 0.653&#160;MeV), such as the shorter half-life and the higher percentage of positron emission, make it the ideal copper nuclide for the labeling of peptides with rapid in vivo clearance. These considerations led us to conduct a broader study that takes us one step closer to translating <sup>61</sup>Cu-based radiopharmaceuticals into clinical practice. Therefore, copper-61 was used to label Tyr3-octreotate (TATE) and compared, in a preclinical setting, with the gold standard [<sup>68</sup>Ga]Ga-DOTA-TATE. The influence of the chelator (i.e., DOTA and NOTA) was also tested to compare the stability of the different copper-chelator complexes. Additionally, in vivo biodistribution studies in AR42J subcutaneous tumor-bearing mice were conducted to confirm the PET/MR imaging abilities of <sup>61</sup>Cu-based radiopharmaceuticals.</p></sec><sec id="Sec2"><title>Results</title><sec id="Sec3"><title>Radiolabeling and quality control</title><p id="Par8">Copper-61 production was performed with an IBA 18/9 cyclotron (IBA&#8211; LouvainLaNeuve, Belgium) at the ICNAS facility (Coimbra, Portugal). [<sup>68</sup>Ga]Ga-DOTA-TATE and [<sup>61</sup>Cu]Cu-DOTA-TATE were radiolabeled as previously described [<xref ref-type="bibr" rid="CR22">22</xref>], while [<sup>61</sup>Cu]Cu-NOTA-TATE was radiolabeled in sodium acetate buffer 2.5&#160;M, under an optimal pH of 4-4.5, for 5 min at 80&#186; C. After radiolabeling, the [<sup>61</sup>Cu]Cu-NOTA-TATE was purified using a C18 column to remove any unreacted [<sup>61</sup>Cu]CuCl<sub>2</sub> and recovered in ethanol: water (50:50). Under the optimized labeling conditions, [<sup>61</sup>Cu]Cu-NOTA-TATE was obtained in radiochemical yields over 95% and molar activities between 18.5&#8211;37 GBq/&#181;mol. Radio-HPLC analysis on EOS consistently showed radiochemical purity above 98%. The retention times of [<sup>68</sup>Ga]Ga-DOTA-TATE, [<sup>61</sup>Cu]Cu-DOTA-TATE, and [<sup>61</sup>Cu]Cu-NOTA-TATE in the optimized HPLC system were between 10&#8217;40&#8217;&#8217; and 10&#8217;55&#8217;&#8217; (details of the method are provided in Table <xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par9">The in vitro stability of [<sup>61</sup>Cu]Cu-NOTA-TATE was evaluated in the final formulation (10% EtOH) to assess the inertness of the metal-complex towards the release of copper-61. The radiolabeled conjugate was found to be stable for at least 6&#160;h after EOS (&gt;&#8201;95% after 6&#160;h of incubation) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). These results are similar to those previously described for [<sup>61</sup>Cu]CuDOTA-TATE (&gt;&#8201;95.6% after 12&#160;h of incubation) [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par10">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>In vitro stability of [<sup>61</sup>Cu]Cu-NOTA-TATE in the final formulation (10% EtOH). Radiochemical purity results were obtained by radioHPLC at: T0, T0&#8201;+&#8201;2&#160;h, T0&#8201;+&#8201;4&#160;h, and T0&#8201;+&#8201;6&#160;h, where T0 represents the EOS. Each data point is expressed as mean&#8201;&#177;&#8201;SEM (<italic toggle="yes">N</italic>&#8201;=&#8201;3)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e500" position="float" orientation="portrait" xlink:href="259_2025_7116_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec4"><title>In vitro uptake of [<sup>68</sup>Ga]Ga-DOTA-TATE, [<sup>61</sup>Cu]Cu-DOTA-TATE, and [<sup>61</sup>Cu]Cu-NOTA-TATE</title><p id="Par11">After successfully radiolabeling the complexes and gaining insight into their in vitro stability, cell uptake studies were performed in SSTR expressing AR42J cells. As expected, all radiopharmaceuticals showed increased uptake with time (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>A). The maximum total uptake of [<sup>68</sup>Ga]Ga-DOTA-TATE, [<sup>61</sup>Cu]Cu-DOTA-TATE, and [<sup>61</sup>Cu]Cu-NOTA-TATE into AR42J was achieved at 2&#160;h and was of 62.5&#8201;&#177;&#8201;1.9%/10<sup>6</sup> cells, 41.6&#8201;&#177;&#8201;2.1%/10<sup>6</sup> cells, 58.6&#8201;&#177;&#8201;3.6%/10<sup>6</sup> cells, respectively. Extended incubation periods beyond 2&#160;h did not result in higher [<sup>61</sup>Cu]Cu-DOTA-TATE and [<sup>61</sup>Cu]Cu-NOTA-TATE uptake levels, indicating the steady-state is reached at 2&#160;h (data not shown). Additionally, both [<sup>68</sup>Ga]Ga-DOTA-TATE and [<sup>61</sup>Cu]Cu-NOTA-TATE exhibited significantly higher uptake compared to [<sup>61</sup>Cu]Cu-DOTA-TATE at all time points. The incubation of the radiolabeled peptides in the presence of a &#8220;cold&#8221; precursor (0.5 &#181;M) resulted in decreased uptake, confirming the specific binding of the radiolabeled SST analogues to the SSTR. Under these conditions, the percentage of uptake for all radiopharmaceuticals was almost negligible (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>B) compared to their corresponding unblocked counterpart, which consistently remained above 3% total uptake.</p><p id="Par12">Figure&#160;<xref rid="Fig2" ref-type="fig">2</xref>C shows the percentage of internalized and membrane-bound fractions over time. Most of the activity was recovered in the glycine buffer wash fraction, with the membrane-bound fraction remaining constant at 3&#8211;5% for [<sup>61</sup>Cu]Cu-DOTA-TATE and increasing slightly to a maximum of 10% for both [<sup>68</sup>Ga]Ga-DOTA-TATE and [<sup>61</sup>Cu]Cu-NOTA-TATE. The intracellular radioactivity was measured upon cell lysis with NaOH. These results confirm that the complexes were efficiently internalized (37.0% for [<sup>61</sup>Cu]Cu-DOTA-TATE, 51.2% for [<sup>68</sup>Ga]Ga-DOTA-TATE, and 51.4% for [<sup>61</sup>Cu]Cu-NOTA-TATE at 2&#160;h incubation time), as predicted based on well-known internalization mechanisms for SST agonists and their respective radiolabeled conjugates [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par13">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>In vitro uptake data of TATE peptide labeled with gallium-68 and copper-61 after incubation of the radiolabeled peptides in SSTR-expressing AR42J cells. Total uptake per million cells over time for (<bold>A</bold>) cells incubated with 0.5 nM [<sup>68</sup>Ga]Ga-DOTA-TATE, [<sup>61</sup>Cu]Cu DOTA-TATE, or [<sup>61</sup>Cu]Cu-NOTA-TATE or (<bold>B</bold>) pre-incubated with 0.5 &#181;M excess of precursor. Each bar is expressed as mean&#8201;&#177;&#8201;SEM (<italic toggle="yes">N</italic>&#8201;=&#8201;3). (<bold>C</bold>) The internalization and membrane-bound fractions of 0.5 nM [<sup>61</sup>Cu]Cu-DOTA-TATE, [<sup>68</sup>Ga]Ga-DOTA-TATE, and [<sup>61</sup>Cu]Cu-NOTA-TATE. The results are expressed as a percentage per million cells (%/10<sup>6</sup> cells). Statistical analysis was carried out using Kruskal-Walli&#8217;s test; *p-value&#8201;&lt;&#8201;0.05 and **p-value&#8201;&lt;&#8201;0.01</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e603" position="float" orientation="portrait" xlink:href="259_2025_7116_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec5"><title>PET/MR imaging of [<sup>68</sup>Ga]Ga-DOTA-TATE, [<sup>61</sup>Cu]Cu-DOTA-TATE, and [<sup>61</sup>Cu]Cu-NOTA-TATE</title><p id="Par14">Animal studies were performed for [<sup>68</sup>Ga]Ga-DOTA-TATE, [<sup>61</sup>Cu]Cu-DOTA-TATE and [<sup>61</sup>Cu]Cu-NOTA-TATE in both healthy controls and tumor-bearing mice. PET/MR images were acquired at 1&#160;h p.i. for all the radiolabeled peptides, which is a typical time-point for imaging with <sup>68</sup>Ga-based radiopharmaceuticals [<xref ref-type="bibr" rid="CR25">25</xref>&#8211;<xref ref-type="bibr" rid="CR27">27</xref>], and additionally at a later time point (4&#160;h p.i.) for the <sup>61</sup>Cu-based radiopharmaceuticals. The activity injected per mouse was kept between 11.5 and 12.5 &#181;Ci/g and the total amount of peptide injected was kept below 0.6 nmol.</p><p id="Par15">The biodistribution profile of [<sup>68</sup>Ga]Ga-DOTA-TATE in AR42J tumor-bearing mice was consistent with previous findings reported in the literature (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>A) [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>], with minor differences, possibly due to variability in tumor size, specific activity of the radiopharmaceutical, and imaging time points. In our study, [<sup>68</sup>Ga]Ga-DOTA-TATE demonstrated faster clearance from non-target organs, including the liver, stomach, and large intestine at 1&#160;h p.i. Furthermore, PET/MR images acquired at 1&#160;h p.i. showed significant tumor and bladder accumulation. On the other hand, the biodistribution profile of [<sup>61</sup>Cu]Cu-DOTA-TATE at 1&#160;h p.i. was significantly different from that observed for [<sup>68</sup>Ga]Ga-DOTA-TATE (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>B). The <sup>61</sup>Cu-based radiopharmaceutical has shown some tumor accumulation, but also high accumulation of radioactivity in non-targeted tissues and organs, particularly in the liver and intestinal tract. These findings suggest that copper-61 undergoes decomplexation from the chelator, thereby affecting the pharmacokinetic properties of the radiolabeled complex. The biodistribution of [<sup>61</sup>Cu]CuCl<sub>2</sub> in healthy mice confirms these findings, showing an accumulation profile of free copper in the liver and the intestine (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>C), similar to that observed with [<sup>61</sup>Cu]Cu-DOTA-TATE. Furthermore, analysis of urine samples by radioHPLC revealed only 81.6% of intact [<sup>61</sup>Cu]Cu-DOTA-TATE (the chromatogram is available in the Supplemental Material section - Figure <xref rid="MOESM1" ref-type="media">S1</xref>B).</p><p id="Par16">The PET/MR images acquired at a later time point (4&#160;h p.i.) with [<sup>61</sup>Cu]Cu-DOTA-TATE confirm the lower tumor accumulation and more dispersed activity in non-target organs compared to 1&#160;h p.i. (Figure <xref rid="MOESM1" ref-type="media">S1</xref>A). This suggest an increased decomplexation of copper-61 over time. This accumulation in non-targeted organs is critical and hinders the possibility of comparison of the performance of gallium-68 and copper-61 isotopes, as the biodistribution profiles of their analogous radiopharmaceuticals are quite different.</p><p id="Par17">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>PET/MR images of DOTA-TATE in tumor-bearing mice 1&#160;h after i.v. injection. (<bold>A</bold>) Representative whole-body PET/MR images of [<sup>68</sup>Ga]Ga-DOTA-TATE in tumor-bearing mice 1&#160;h after i.v. injection. (<bold>B</bold>) Representative whole-body PET/MR images of [<sup>61</sup>Cu]Cu-DOTA-TATE in tumor-bearing mice 1&#160;h after injection. (<bold>C</bold>) Representative whole-body PET/MR images of [<sup>61</sup>Cu]CuCl<sub>2</sub> in control mice 1&#160;h after injection</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e707" position="float" orientation="portrait" xlink:href="259_2025_7116_Fig3_HTML.jpg"/></fig>
</p><p id="Par18">PET/MR images of [<sup>61</sup>Cu]Cu-NOTA-TATE at 1&#160;h and 4&#160;h p.i. in healthy control mice (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>A and B) showed rapid clearance with marked accumulation in the kidneys and bladder, indicated renal excretion as the primary elimination route for [<sup>61</sup>Cu]Cu-NOTA-TATE. The fast blood clearance of [<sup>61</sup>Cu]Cu-NOTA-TATE was confirmed by blood sampling with 0.13&#8201;&#177;&#8201;0.02% ID/g at 2&#160;h, which further decreased to 0.09&#8201;&#177;&#8201;0.004% ID/g at 4&#160;h p.i. (Figure S2A). This rapid clearance, accompanied by low uptake in all organs, resulted in a low background for tumor imaging and suggests high in vivo stability of [<sup>61</sup>Cu]Cu-NOTA-TATE. Next, we investigated the tumor targeting of [<sup>61</sup>Cu]Cu-NOTA-TATE in nude mice bearing AR42J tumours. PET/MR images (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>C and D) showed a biodistribution profile similar to that of control mice with accumulation of the radiopharmaceutical in the tumor. This biodistribution profile is also similar to that observed for [<sup>68</sup>Ga]Ga-DOTA-TATE. This is consistent with radioHPLC analysis of urine samples (Figure S2B), which showed 100% radiochemically stability of [<sup>61</sup>Cu]Cu-NOTA-TATE. The later time-point (4&#160;h p.i.) PET/MR image with [<sup>61</sup>Cu]Cu-NOTA-TATE (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>D) showed lower background activity and a higher tumor-to-background contrast.</p><p id="Par19">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>PET/MR images of [<sup>61</sup>Cu]Cu-NOTA-TATE in control mice and AR42J tumor-bearing mice. (<bold>A</bold>) Representative whole-body PET/MR images of [<sup>61</sup>Cu]Cu-NOTA-TATE 1&#160;h after <italic toggle="yes">i.v.</italic> injection in control mice. (<bold>B</bold>) Representative whole-body PET/MR images of [<sup>61</sup>Cu]CuNOTATATE 4&#160;h after <italic toggle="yes">i.v.</italic> injection in control mice. (<bold>C</bold>) Representative whole-body PET/MR images of [<sup>61</sup>Cu]Cu-NOTA-TATE 1&#160;h after <italic toggle="yes">i.v.</italic> injection in AR42J tumor-bearing mice. (<bold>D</bold>) Representative whole-body PET/MR images of [<sup>61</sup>Cu]Cu-NOTA-TATE 4&#160;h after <italic toggle="yes">i.v.</italic> injection in AR42J tumor-bearing mice</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e782" position="float" orientation="portrait" xlink:href="259_2025_7116_Fig4_HTML.jpg"/></fig>
</p></sec><sec id="Sec6"><title>Biodistribution studies of [<sup>68</sup>Ga]Ga-DOTA-TATE, [<sup>61</sup>Cu]Cu-DOTA-TATE, and [<sup>61</sup>Cu]Cu-NOTA-TATE</title><p id="Par20">To confirm the imaging results, mice were sacrificed at 1&#160;h p.i. or 4&#160;h p.i., and organs were harvested for radioactivity quantification using a &#947;-counter. The biodistribution studies in tumor-bearing mice at 4&#160;h p.i. for [<sup>61</sup>Cu]Cu-DOTA-TATE and in control mice at 4&#160;h p.i. for [<sup>61</sup>Cu]Cu-NOTA-TATE can be found in the supplemental material section in Figure <xref rid="MOESM1" ref-type="media">S1</xref>C and Figure S2C, respectively.</p><p id="Par21">The ex vivo biodistribution results of [<sup>61</sup>Cu]Cu-NOTA-TATE (<italic toggle="yes">N</italic>&#8201;=&#8201;3) and [<sup>68</sup>Ga]Ga-DOTA-TATE (<italic toggle="yes">N</italic>&#8201;=&#8201;3) on tumor-bearing mice are shown in Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>A. At 1&#160;h p.i. the radioactivity of [<sup>61</sup>Cu]Cu-NOTA-TATE in the kidneys was similar to that of [<sup>68</sup>Ga]Ga-DOTA-TATE and higher than that at 4&#160;h p.i., confirming the renal excretion of the radiolabeled peptides. The radioactivity of [<sup>68</sup>Ga]Ga-DOTA-TATE in the spleen and lungs was higher than that of [<sup>61</sup>Cu]Cu-NOTA-TATE, whereas the liver showed no significant difference in radioactivity uptake. Both complexes showed low accumulation in non-target organs, namely the heart, bones, muscle, and brain. The stomach, intestines, and feces showed marginal accumulation, less than 2% ID/g. After 1&#160;h of i.v. injection the blood activity of [<sup>68</sup>Ga]Ga-DOTA-TATE and [<sup>61</sup>Cu]Cu-NOTA-TATE was only 0.43&#8201;&#177;&#8201;0.06% ID/g and 0.19&#8201;&#177;&#8201;0.003% ID/g, respectively. The tumor had the highest uptake of all organs for both compounds at both time points. For [<sup>68</sup>Ga]Ga-DOTA-TATE, the tumor activity at 1&#160;h was 8.73&#8201;&#177;&#8201;0.45% ID/g, whereas for [<sup>61</sup>Cu]Cu-NOTA-TATE, it was 13.25&#8201;&#177;&#8201;1.86% ID/g and 12.81&#8201;&#177;&#8201;0.57% ID/g at 1&#160;h and 4&#160;h p.i., respectively. The high percentage of radioactivity at 4&#160;h p.i. indicates an irreversible accumulation of the radiopharmaceutical in the tumor.</p><p id="Par22">The tumor-to-muscle and tumor-to-kidney ratios (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>B and C, respectively) were quite similar for [<sup>68</sup>Ga]Ga-DOTA-TATE (tumor-to-muscle: 274.01&#8201;&#177;&#8201;77.25 and tumor-to-kidney: 3.01&#8201;&#177;&#8201;0.52) and [<sup>61</sup>Cu]Cu-NOTA-TATE (tumor-to-muscle: 254.72&#8201;&#177;&#8201;64.72 and tumor-to-kidney: 4.25&#8201;&#177;&#8201;1.09) at 1&#160;h p.i. However, these ratios increased at 4&#160;h p.i. for [<sup>61</sup>Cu]Cu-NOTA-TATE (tumor-to-muscle: 494.81&#8201;&#177;&#8201;109.31 and tumor-to-kidney: 17.32&#8201;&#177;&#8201;4.99). In contrast, the tumor-to-liver ratio was higher for [<sup>61</sup>Cu]Cu-NOTA-TATE at both time points (14.08&#8201;&#177;&#8201;4.29 at 1&#160;h p.i. and 21.04&#8201;&#177;&#8201;1.28 at 4&#160;h p.i.) compared to [<sup>68</sup>Ga]Ga-DOTA-TATE (2.46&#8201;&#177;&#8201;0.55) at 1&#160;h p.i. (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>D).</p><p id="Par23">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Ex vivo quantification of organ biodistribution data determined by gamma counting after the last imaging timepoint. (<bold>A</bold>) Organ biodistribution of [<sup>68</sup>Ga]Ga-DOTA-TATE and [<sup>61</sup>Cu]Cu-NOTA-TATE was performed after the 1&#160;h imaging timepoint, and for [<sup>61</sup>Cu]Cu-NOTA-TATE organs were collected after the 4&#160;h imaging. Mice were sacrificed, perfused with PBS and whole organs were excised for quantitative analysis. Values were normalized to grams of tissue per injected dose and expressed as mean&#8201;&#177;&#8201;SEM (<italic toggle="yes">N</italic>&#8201;=&#8201;3). (<bold>B</bold>) Tumor-to-muscle, (<bold>C</bold>) Tumor-to-kidney, (<bold>D</bold>) Tumor-to-liver ratios of each radiopharmaceutical determined at the time of sacrifice</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e885" position="float" orientation="portrait" xlink:href="259_2025_7116_Fig5_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec7"><title>Discussion</title><p id="Par24"><sup>68</sup>Ga-based radiopharmaceuticals labeled with SST agonists, particularly [<sup>68</sup>Ga]Ga-DOTA-TATE, [<sup>68</sup>Ga]Ga-DOTA-TOC, and [<sup>68</sup>Ga]Ga-DOTA-NOC, play a significant role in the clinical diagnosis, stagging, and selection of treatment in patients with highly differentiated NETs [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Compared to gallium-68 (T<sub>1/2</sub> = 1.13&#160;h, 89% &#946;+, Emax&#8201;=&#8201;1.899&#160;MeV), copper-61 has excellent physical decay properties (T<sub>1/2</sub> = 3.33&#160;h, 61% &#946;+, Emax&#8201;=&#8201;1.216&#160;MeV) for PET imaging with peptide-based radiopharmaceuticals, allowing flexibility of the imaging window with potential improved tumor-to-background ratios. Furthermore, it has additional advantages such as cost-effective production method and facilitating the centralized production and distribution of <sup>61</sup>Cu-based radiopharmaceuticals due to its longer half-life [<xref ref-type="bibr" rid="CR21">21</xref>]. Previous data have shown that <sup>64</sup>Cu-labelled SST agonists have a profound impact on the PET performance of NETs imaging [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR30">30</xref>], significantly improving lesion detection.</p><p id="Par25">DOTA is a standard chelator used in the clinical practice. Not only have <sup>68</sup>Ga-DOTA derivatives demonstrated good pharmacokinetic properties and high stability in vivo for various applications, but their therapeutic counterparts, labeled with lutetium-177, have also demonstrated high safety and efficacy for human application in different pathologies [<xref ref-type="bibr" rid="CR31">31</xref>&#8211;<xref ref-type="bibr" rid="CR34">34</xref>]. The versatility of DOTA has greatly contributed to its widespread use, making it the most widely used chelator for incorporation of transition metal-based radiopharmaceuticals. Moreover, copper-based radiopharmaceuticals, particularly copper-64 radiopharmaceuticals also incorporate DOTA in their structure. However, several studies have shown that the use of Cu-DOTA complexes conjugated to different peptides results in increased activity uptake in non-targeted organs such as the liver and intestine [<xref ref-type="bibr" rid="CR35">35</xref>&#8211;<xref ref-type="bibr" rid="CR38">38</xref>]. In particular, high activity accumulation in non-targeted organs has been reported for various <sup>64</sup>Cu-labelled SST agonists [<sup>64</sup>Cu]Cu-DOTA-TOC and [<sup>64</sup>Cu]Cu-DOTA-TATE due to decomplexation of the radioisotope from the radiopharmaceutical, associated with the instability of the Cu-DOTA complex [<xref ref-type="bibr" rid="CR39">39</xref>&#8211;<xref ref-type="bibr" rid="CR41">41</xref>]. To improve the stability of <sup>64</sup>Cu-based radiopharmaceuticals, some authors have suggested the use of another polyamine carboxylate chelator NOTA. Cu-NOTA conjugates demonstrated increased stability [<xref ref-type="bibr" rid="CR42">42</xref>] and, consequently improved pharmacokinetic properties, resulting in lower accumulation in the liver and non-targeted organs compared to their Cu-DOTA analogues [<xref ref-type="bibr" rid="CR43">43</xref>&#8211;<xref ref-type="bibr" rid="CR45">45</xref>]. However, the incorporation of Cu-NOTA complexes into copper-based radiopharmaceuticals has been limited to small preclinical studies. More recently the incorporation of sarcophagine-based (SAR) chelators in clinical trials (ClinicalTrials.gov ID: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04868604">NCT04868604</ext-link>, ID: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05407311">NCT05407311</ext-link>) has been a strategy adopted to improve the properties of copper-based radiopharmaceuticals.</p><p id="Par26">In the present study, our primary focus was to investigate the possibility of using a <sup>61</sup>Cu-based radiopharmaceutical as an alternative to the widely used gallium-68 analogue for imaging NETs. Additionally, we evaluated the effect of the bifunctional chelator (BFC) on the pharmacokinetic properties and tumor uptake by labeling the SST agonist Tyr3-octreotate (TATE) with copper-61 using two different conjugates: DOTA-TATE and NOTA-TATE.</p><p id="Par27">Compared to [<sup>61</sup>Cu]Cu-DOTA-TATE, [<sup>61</sup>Cu]Cu-NOTA-TATE (pH&#8201;&#177;&#8201;4.0) can be prepared at room temperature (RT) with shorter incubation time (5&#160;min). Both radiolabeled peptides present high radiochemical purity and similar in vitro stability. The molar activity achieved for the two <sup>61</sup>Cu-based radiopharmaceuticals was also similar, ranging from 18.5 to 37.0 GBq/&#181;mol.</p><p id="Par28">In vitro uptake studies reveal a higher internalization rate for the [<sup>68</sup>Ga]Ga-DOTA-TATE and [<sup>61</sup>Cu]Cu-NOTA-TATE conjugates compared to [<sup>61</sup>Cu]Cu-DOTA-TATE. Changes in the affinity profiles and internalization are often observed due to slight modifications in the peptide sequence, chelator, or radiometal used [<xref ref-type="bibr" rid="CR46">46</xref>&#8211;<xref ref-type="bibr" rid="CR48">48</xref>]. Structurally, copper(II) forms a distorted octahedral complex when chelated with DOTA, coordinated to all nitrogen atoms of the macrocycle and two translocated carboxylate groups [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. Ga-DOTA forms a hexacoordinated complex with the same ligand donor atoms. However, due to the oxidation state of gallium (+&#8201;3), the [<sup>68</sup>Ga]Ga-DOTA-TATE complex most likely has a neutral charge under physiological conditions [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. On the other hand, copper(II) forms a pentadentate complex with the NOTA chelator, resulting in an overall neutral charge in its coordination sphere. These differences in the overall charge of the complexes can have a significant impact on the overall internalization and binding properties of each tracer.</p><p id="Par29">For dynamic PET/MR imaging, the amount of peptide injected per mice was kept below 0.6 nmol, as a previous study using the same animal model, demonstrated the effect of peptide amount on tumor uptake [<xref ref-type="bibr" rid="CR53">53</xref>]. PET/MR images of AR42J subcutaneous tumor-bearing mice confirmed the superior pharmacokinetic properties of [<sup>61</sup>Cu]Cu-NOTA-TATE over [<sup>61</sup>Cu]Cu-DOTA-TATE complexes. It is hypothesized that the overall neutral charge and lipophilicity of the [<sup>61</sup>Cu]Cu-NOTA-TATE conjugate may improve the biodistribution profile and help overcome prolonged retention in non-targeted organs [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. Recently, similar results were observed for [<sup>68</sup>Ga]Ga-DOTA-TATE and [<sup>68</sup>Ga]Ga-NOTA-TATE. Both radiopeptides showed comparable tumor uptake (3.14&#8201;&#177;&#8201;2.07% vs. 3.16&#8201;&#177;&#8201;1.92%), however the SUV max for [<sup>68</sup>Ga]Ga-NOTA-TATE was lower in most organs [<xref ref-type="bibr" rid="CR29">29</xref>]. This difference was attributed to variations in renal activity uptake due to differences in charge and size. In our study, the high activity uptake in non-targeted organs with [<sup>61</sup>Cu]Cu-DOTA-TATE suggests decomplexation of copper-61 from the chelator, which also correlates with previous findings for other Cu-DOTA conjugates [<xref ref-type="bibr" rid="CR39">39</xref>&#8211;<xref ref-type="bibr" rid="CR41">41</xref>]. This was further supported by the similarities with the biodistribution profile of free [<sup>61</sup>Cu]CuCl<sub>2</sub>. In addition, tumor uptake of [<sup>61</sup>Cu]Cu-NOTA-TATE was significantly higher at 4&#160;h p.i. (12.81&#8201;&#177;&#8201;0.57% ID/g), suggesting that [<sup>61</sup>Cu]Cu-NOTA-TATE is a better candidate for clinical translation.</p><p id="Par30">Compared to [<sup>68</sup>Ga]Ga-DOTA-TATE, the tumor uptake of [<sup>61</sup>Cu]Cu-NOTA-TATE appears to be higher at 1&#160;h p.i., however this difference is not significant. The biodistribution of both is very similar within the 1&#160;h imaging. At 4&#160;h p.i. the <sup>61</sup>Cu-labeled conjugate allows improved visualization of SSTR expressing tumors, as the tumor uptake exceeds that of normal tissue, with prolonged activity retention in tumor tissue. This was further confirmed by the tumor-to-muscle and tumor-to-kidney ratios for [<sup>61</sup>Cu]Cu-NOTA-TATE which increased over time, while the tumor-to-liver remains constant. The animal experiments performed in this study corroborate the hypothesis that [<sup>61</sup>Cu]Cu-NOTA-TATE can be used as a PET imaging agent as an alternative to [<sup>68</sup>Ga]Ga-DOTA-TATE. The images at the latter time point reflect what was expected based on previous studies with copper-64, with an improved tumor-to-background ratio and the possibility of an extended imaging window, at least up to 4&#160;h p.i. [<xref ref-type="bibr" rid="CR18">18</xref>].</p></sec><sec id="Sec8"><title>Conclusion</title><p id="Par31">In this study, the SST agonist (TATE) was radiolabeled with copper-61, in the form of two different radioconjugates: [<sup>61</sup>Cu]Cu-DOTA-TATE and [<sup>61</sup>Cu]Cu-NOTA-TATE. Independent of the mechanism, PET/MR images and ex vivo biodistribution in control and tumor-bearing mice showed that [<sup>61</sup>Cu]Cu-NOTA-TATE outperforms [<sup>61</sup>Cu]Cu-DOTA-TATE in this xenograft animal model. Furthermore, [<sup>61</sup>Cu]Cu-NOTA-TATE was characterized by fast clearance in vivo and specific uptake in tumor xenografts. Importantly, the longer half-life of copper-61 (3.33&#160;h) compared to gallium-68 (68&#160;min) allowed imaging to be extended up to 4&#160;h p.i., resulting in improved pharmacokinetic properties. The flexibility of the imaging window is not only one of the advantages for the daily routine of PET imaging, but also an indispensable tool when considering matching the image biodistribution with therapeutic radionuclides with longer half-lives. Taken together, these findings indicate the potential usefulness of <sup>61</sup>Cu-based radiotracers for tumor localization, staging, and therapy follow up with increased potential for clinical translation.</p></sec><sec id="Sec9"><title>Materials and methods</title><p id="Par32">All chemicals and solvents used for the purification of [<sup>61</sup>Cu]CuCl<sub>2</sub> and [<sup>68</sup>Ga]GaCl<sub>3</sub>, and for the synthesis of <sup>68</sup>Ga- and <sup>61</sup>Cu-conjugated peptides were trace metal grade. The HPLC solvents were also HPLC grade. Other solvents and reagents (i.e., HCl&#8201;&gt;&#8201;30% and HNO<sub>3</sub>&#8201;&gt;&#8201;69% (Honeywell Fluka - Charlotte, North Carolina, USA), bi-distilled water (BBraun - Melsungen, Germany), ethanol (Rotem, Israel), sodium acetate anhydrous (Honeywell Fluka), L-ascorbic acid (Sigma-Aldrich - St. Louis, Missouri, USA) and DTPA (Alfa Aesar - Kandel, Germany) were also trace metal basis, to prevent metal cross-contamination.</p><p id="Par33">Zinc nitrate (99.998%) was acquired from Alfa Aesar (Kandel, Germany), while the enriched zinc-68 solution (66&#160;mg/mL) was purchased from Fluidomica (Cantanhede, Portugal). Disposable purification and labeling kits for both copper-61 and gallium-68 purification were also purchased from Fluidomica (Cantanhede, Portugal). The peptides DOTA-TATE acetate, NODAGA-LM3 and NOTA-TATE were fractionated and kept at -20&#160;&#176;C in an aqueous solution. DOTA-TATE was manufactured by ABX (Radeberg, Germany), while the remaining peptides were manufactured by Pepmic (Suzhou, China).</p><sec id="Sec10"><title>Preparation of [<sup>61</sup>Cu]CuCl<sub>2</sub></title><p id="Par34">Irradiation of natural zinc liquid targets and further purification of copper-61 was performed according to the previously published and described methodology [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. Briefly, copper-61 was obtained from the irradiation of natural zinc solutions using an IBA Cyclone 18/9 (IBA - Louvain-la-Neuve, Belgium). Natural zinc was supplied by Alfa Aesar (Thermo Fisher Scientific - Lancashire, UK) and dissolved in 0.01&#160;M HNO<sub>3</sub> to a concentration of 200&#160;mg/mL. These solutions were irradiated under incident proton energy of 16.9&#160;MeV. The resulting target solution was transferred to a shielded hot-cell, and automated copper-61 purification was performed using a Synthera<sup>&#174;</sup> Extension module (IBA - Louvain-la-Neuve, Belgium), without any manual intervention. All reagents and the tubing kit were supplied by Fluidomica (Cantanhede, Portugal). The final copper chloride solution was ready for labelling 35&#160;min after EOB.</p></sec><sec id="Sec11"><title>Preparation of [<sup>68</sup>Ga]GaCl<sub>3</sub></title><p id="Par35">Irradiation of zinc-68 liquid targets and further gallium-68 purification was performed according to previously published and described methodology [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. Briefly, gallium-68 was obtained by irradiation of zinc-68 solutions using an IBA Kiube variable energy (IBA - Louvain-la-Neuve, Belgium). The zinc-68 solution was supplied by Fluidomica (Cantanhede, Portugal). These solutions were irradiated under an incident proton energy of 16.9&#160;MeV. The resulting target solution was transferred to a shielded hot-cell, and gallium-68 automatic purification was performed using a Synthera<sup>&#174;</sup> Extension module (IBA - Louvain-la-Neuve, Belgium), without manual intervention. All reagents and tubing kits were provided by Fluidomica (Cantanhede, Portugal). The final gallium chloride solution was ready for labeling 40&#160;min after EOB.</p></sec></sec><sec id="Sec12"><title>Radiolabeling with copper-61 and gallium-68</title><sec id="Sec13"><title>Synthesis of [<sup>61</sup>Cu]Cu-DOTA-TATE and [<sup>61</sup>Cu]Cu-NOTA-TATE</title><p id="Par36">The synthesis of [<sup>61</sup>Cu]Cu-DOTA-TATE was performed as previously described [<xref ref-type="bibr" rid="CR22">22</xref>]. The radiolabeling of NOTA-TATE with copper-61 was performed using a similar methodology. Briefly, the 10&#160;&#181;g of the precursor NOTA-TATE was reacted directly with copper chloride in sodium acetate buffer (2.5&#160;M) at approximate pH of 4.5, 80&#186; C for 5&#160;min. The radiolabeled conjugate was purified using a preconditioned (10 mL of ethanol, followed by 10 mL water) C18 cartridge (Waters<sup>&#8482;</sup> - Milford, MA, EUA).</p></sec><sec id="Sec14"><title>Synthesis of [<sup>68</sup>Ga]Ga-DOTA-TATE</title><p id="Par37">The fully automated synthesis of [<sup>68</sup>Ga]Ga-DOTA-TATE was performed using the Synthera Extension module following a similar methodology as described [<xref ref-type="bibr" rid="CR59">59</xref>]. After purification, gallium-68 chloride was concentrated using a Bond Elut SCX (Agilent Technologies&#8211; CA, USA) and finally eluted with a solution of 0.5&#160;M NaCl in 0.05&#160;M HCl for the reactor vial. The synthesis of [<sup>68</sup>Ga]Ga-DOTA-TATE, was performed in the presence of 1 mL of HEPES (0.5&#160;M) and ascorbic acid (&#177;&#8201;5&#160;&#181;g), at a pH between 3 and 3.5 and incubated at 100&#186; C for 10&#160;min. The radiolabeled conjugate was purified using an HLB SPE cartridge (Waters<sup>&#8482;</sup> - Milford, MA, EUA).</p></sec><sec id="Sec15"><title>Radiochemical purity</title><p id="Par38">The radiochemical purity of [<sup>61</sup>Cu]Cu-DOTA-TATE, [<sup>61</sup>Cu]Cu-NOTA-TATE, and [<sup>68</sup>Ga]Ga-DOTA-TATE was evaluated by radio-HPLC performed on an Agilent HPLC (model Agilent 1260 Infinity II) using an ACE 3 C18 column (ACE - Reading, UK) at 0.6 mL/min. The HPLC method used is detailed in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>.</p><p id="Par39">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>HPLC method for determination of RCP of each radiopharmaceutical</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Time (min)</th><th align="left" colspan="1" rowspan="1">Mobile Phase A<break/>(Per Cent v/v)</th><th align="left" colspan="1" rowspan="1">Mobile Phase B<break/>(Per Cent v/v)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Solvents</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Water/0.1% TFA</td><td align="left" colspan="1" rowspan="1">ACN/0.1% TFA</td></tr><tr><td align="left" rowspan="3" colspan="1">Gradient</td><td align="left" colspan="1" rowspan="1">0&#8211;8</td><td align="left" colspan="1" rowspan="1">78</td><td align="left" colspan="1" rowspan="1">22</td></tr><tr><td align="left" colspan="1" rowspan="1">8&#8211;9</td><td align="left" colspan="1" rowspan="1">78 &#8594; 40</td><td align="left" colspan="1" rowspan="1">22 &#8594; 60</td></tr><tr><td align="left" colspan="1" rowspan="1">9&#8211;14</td><td align="left" colspan="1" rowspan="1">40</td><td align="left" colspan="1" rowspan="1">60</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec16"><title>Stability</title><p id="Par40">The stability of [<sup>61</sup>Cu]Cu-NOTA-TATE was tested in the final formulation up to 6&#160;h after EOS. At different time points (T0, T0&#8201;+&#8201;2, T0&#8201;+&#8201;4 and T0&#8201;+&#8201;6&#160;h) aliquots were taken and measured using the previously described radioHPLC method.</p></sec><sec id="Sec17"><title>Cell culture</title><p id="Par41">The AR42J cell line, a natural SSTR-overexpressing epithelial-like cell isolated from a rat pancreatic tumor, was purchased from American Type Culture Collection (ATCC, CRL-1492) (Manassas, VA, USA) and cultured in F-12&#160;K medium (ATCC, Catalog No. 30-2004) supplemented with 20% heat-inactivated fetal bovine serum (FBS, Gibco) and 1% PenStrep. The cells were maintained under standard adherent conditions in a humidified incubator with 5% CO<sub>2</sub> at 37&#176; C.</p></sec><sec id="Sec18"><title>Internalization studies</title><p id="Par42">Internalization assays of [<sup>61</sup>Cu]Cu-DOTA-TATE and [<sup>68</sup>Ga]Ga-DOTA-TATE were performed in AR42J cells seeded at a density of 0.75&#160;million per well in 6-well culture plates and allowed to attach for 48&#160;h. Cells were incubated at 37&#186; C for a maximum of 2&#8211;4&#160;h (15&#160;min, 30&#160;min, 1&#160;h, 2&#160;h, and 4&#160;h) for <sup>68</sup>Ga-based and <sup>61</sup>Cu-based radiopharmaceuticals, respectively. At the indicated time points, the cellular uptake was terminated by washing the cells with PBS. Cell surface-bound radioactivity was removed by an acid wash (50 mM glycine, pH 2.8) at RT for 5&#160;min. The pH was neutralized with PBS, and the cells were lysed by incubation with 1&#160;M NaOH at 37<sup>o</sup> C for 5&#160;min to determine internalized radioactivity. Each experiment was performed in triplicate. The radioactivity associated with each fraction was measured in a CRC-55tW gamma well counter (Mirion Technologies - Atlanta, GA, USA), and expressed as a percentage of the total activity added to the cells after decay correction and presented as mean&#8201;&#177;&#8201;SEM. For blocking studies, parallel experiments were performed as described above, but cells were incubated in the presence of DOTA-TATE precursor (0.5 &#181;M) at 37&#186; C for the same time points.</p></sec><sec id="Sec19"><title>Animal model</title><p id="Par43">Animal studies were approved by the Animal Welfare Committee of the Institute for Nuclear Sciences Applied to Health (ICNAS) of University of Coimbra (ORBEA 05-2024) and by the Portuguese National Authority for Animal Health (DGAV). Athymic male Swiss Foxn1nu mice (28&#8211;32&#160;g, 6&#8211;8 weeks old) were purchased from ICNAS and housed under pathogen free conditions in individually ventilated cages. To establish the tumor model, animals were injected subcutaneously in the left flank with 3&#8201;&#215;&#8201;10<sup>6</sup> AR42J cells resuspended in 100 &#181;L of PBS 50 with 50% Matrigel. Tumor growth was monitored twice weekly by caliper measurements and were allowed to grow to a maximum volume of 1 cm<sup>3</sup>.</p></sec><sec id="Sec20"><title>PET/MR imaging</title><p id="Par44">Tumor-bearing mice were injected intravenously into the tail vein with [<sup>61</sup>Cu]Cu-DOTA-TATE (<italic toggle="yes">N</italic>&#8201;=&#8201;3), [<sup>61</sup>Cu]Cu-NOTA-TATE (<italic toggle="yes">N</italic>&#8201;=&#8201;3), or [<sup>68</sup>Ga]Ga-DOTA-TATE (<italic toggle="yes">N</italic>&#8201;=&#8201;3) (&#8804;&#8201;0.5 nmols; 11.5 to 12.5 &#181;Ci/g) in 150 &#181;L of PBS and were imaged under anesthesia (1&#8211;2% isoflurane) in a prototype high-resolution small animal PET scanner based on resistive plate chambers (RPC-PET). A set of fiducial markers was used for an optimal PET/MRI co-registration. The breathing rate and body temperature of the animals were monitored throughout the imaging procedures (SA Instruments SA, USA). After the PET scan, a whole-body MRI was performed on a BioSpec 9.4T MRI scanner with a body volume resonator (transmitter/receiver) with the animal in the same position for anatomical co-localization. Anatomical reference images were obtained from axial and coronal multi-slice scans. A set of fiducial markers were used on the animal bed for an optimal PET/MRI co-registration. Quantitative image processing was performed using PMOD (PMOD, v 3.6; PMOD Technologies, Z&#252;rich, Switzerland, RRID: SCR_016547). FUSION Tools were used to deliniate volumes of interest (VOIs) on the PET images co-registered with the anatomical MRI. Blood samples were collected at 1, 2, and 4&#160;h after injection for measurement of whole-blood radioactivity concentrations.</p></sec><sec id="Sec21"><title>Ex vivo biodistribution</title><p id="Par45">Mice were sacrificed at 1.5&#8211;4.5&#160;h p.i. and perfused with PBS. Organs including brain, heart, lung, liver, kidney, spleen, stomach, intestine, bone, and muscle were collected and weighted. Blood samples were collected via tail vein bleeding at different time points to monitor the residence time of the radiopharmaceuticals in the circulation. After sacrifice, urine was directly collected from the bladder for radio-HPLC analysis of radiopharmaceutical integrity. The radioactivity of each sample was measured using an automated CRC-55tW gamma well counter (Mirion Technologies - Atlanta, GA, USA). Results were expressed as the percentage of injected dose per gram (ID/g) of tissue and presented as the mean&#8201;&#177;&#8201;SEM (<italic toggle="yes">N</italic>&#8201;=&#8201;3 per radiopharmaceutical).</p></sec></sec><sec id="Sec22"><title>Biological samples radioHPLC analysis</title><p id="Par46">Urine samples were collected at the time of the sacrifice. The samples were centrifuged at 5 000&#160;rpm for 5&#160;min and the supernatant was collected. The radiochemical integrity of the radiopeptides in the urine was evaluated using radioHPLC. The analysis was carried out on an ACE 3 C18 column (ACE - Reading, UK) with an installed pre-column (Marca, country) at a flow rate of 1.2 mL/min. The detailed HPLC method used is shown in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>.</p><p id="Par47">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>HPLC method for determination of RCP in biological samples</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Time (min)</th><th align="left" colspan="1" rowspan="1">Mobile Phase A<break/>(Per Cent v/v)</th><th align="left" colspan="1" rowspan="1">Mobile Phase B<break/>(Per Cent v/v)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Solvents</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Water/0.1% TFA</td><td align="left" colspan="1" rowspan="1">ACN/0.1% TFA</td></tr><tr><td align="left" rowspan="3" colspan="1">Gradient</td><td align="left" colspan="1" rowspan="1">0&#8211;8</td><td align="left" colspan="1" rowspan="1">78</td><td align="left" colspan="1" rowspan="1">22</td></tr><tr><td align="left" colspan="1" rowspan="1">8&#8211;9</td><td align="left" colspan="1" rowspan="1">78 &#8594; 40</td><td align="left" colspan="1" rowspan="1">22 &#8594; 60</td></tr><tr><td align="left" colspan="1" rowspan="1">9&#8211;14</td><td align="left" colspan="1" rowspan="1">40</td><td align="left" colspan="1" rowspan="1">60</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec23" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="259_2025_7116_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualization, AIF, FA and AJA; methodology, AIF, JS, SA, IH and HF; validation, AIF, JS, SA, HF, CG, and AJA; investigation, FA and AJA; resources, AF, AJA, CG and FA; data curation, AIF, JS and SA; visualization and writing&#8212;original draft preparation, AIF, SA, and IH; writing&#8212;review and editing, CG and AJA; supervision, CG, AF, FA and AJA; project administration, FA and AJA. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by FCT|FCCN (b-on).</p><p>This work was founded by the Portuguese Foundation for Science and Technology (FCT) through PhD grants (grant number PD/BDE/150681/2020) and by ICNAS Pharma.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets that were used and/or analyzed in this study can be found within the article and its supplementary material. For additional information, please make a reasonable request to the corresponding author.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par48">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par49">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par50">The authors declare no conflict of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zwan</surname><given-names>JM van der</given-names></name><name name-style="western"><surname>Trama</surname><given-names>A</given-names></name><name name-style="western"><surname>Otter</surname><given-names>R</given-names></name><name name-style="western"><surname>Larra&#241;aga</surname><given-names>N</given-names></name><name name-style="western"><surname>Tavilla</surname><given-names>A</given-names></name><name name-style="western"><surname>Marcos-Gragera</surname><given-names>R</given-names></name><etal/></person-group><article-title>Rare neuroendocrine tumours: results of the surveillance of rare cancers in Europe project</article-title><source>Eur J Cancer</source><year>2013</year><volume>49</volume><issue>11</issue><fpage>2565</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2013.02.029</pub-id><pub-id pub-id-type="pmid">23541566</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal"> van der Zwan JM, Trama A, Otter R, Larra&#241;aga N, Tavilla A, Marcos-Gragera R, et al. Rare neuroendocrine tumours: results of the surveillance of rare cancers in Europe project. Eur J Cancer. 2013;49(11):2565&#8211;78.<pub-id pub-id-type="pmid">23541566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2013.02.029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Vahidfar N, Farzanehfar S, Abbasi M, Mirzaei S, Delpassand ES, Abbaspour F et al. Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [64Cu]Cu-DOTA-TOC. Cancers (Basel). 2022;14(1914).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers14081914</pub-id><pub-id pub-id-type="pmcid">PMC9027354</pub-id><pub-id pub-id-type="pmid">35454822</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reubi</surname><given-names>JC</given-names></name></person-group><article-title>Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment</article-title><source>Neuroendocrinology</source><year>2004</year><volume>80</volume><issue>Suppl 1</issue><fpage>51</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1159/000080742</pub-id><pub-id pub-id-type="pmid">15477718</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Reubi JC. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology. 2004;80(Suppl 1):51&#8211;6.<pub-id pub-id-type="pmid">15477718</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000080742</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: Biological, chemical and therapeutic aspects. Nature Reviews Drug Discovery. Volume 2. European Association for Cardio-Thoracic Surgery; 2003. pp. 999&#8211;1017.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd1255</pub-id><pub-id pub-id-type="pmid">14654798</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krenning</surname><given-names>EP</given-names></name><name name-style="western"><surname>Breeman</surname><given-names>WAP</given-names></name><name name-style="western"><surname>Kooij</surname><given-names>PPM</given-names></name><name name-style="western"><surname>Lameris</surname><given-names>JS</given-names></name><name name-style="western"><surname>Bakker</surname><given-names>WH</given-names></name><name name-style="western"><surname>Koper</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Localisation of endocrine-related Tumours with Radioiodinated Analogue of somatostatin</article-title><source>Lancet</source><year>1989</year><volume>333</volume><fpage>242</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(89)91258-0</pub-id><pub-id pub-id-type="pmid">2563413</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Krenning EP, Breeman WAP, Kooij PPM, Lameris JS, Bakker WH, Koper JW, et al. Localisation of endocrine-related Tumours with Radioiodinated Analogue of somatostatin. Lancet. 1989;333:242&#8211;4.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0140-6736(89)91258-0</pub-id><pub-id pub-id-type="pmid">2563413</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Kwekkeboom DJ, Krenning EP, Scheidhauer K, Lawington V. ENETS Consensus guidelines for the standards of Care in neuroendocrine tumors: somatostatin receptor imaging with 111In-Pentetreotide. Neuroendocrinology. 2009;(90):184&#8211;9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000225946</pub-id><pub-id pub-id-type="pmid">19713709</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krenning</surname><given-names>EP</given-names></name><name name-style="western"><surname>Bakker</surname><given-names>WH</given-names></name><name name-style="western"><surname>Kooij</surname><given-names>PPM</given-names></name><name name-style="western"><surname>Breeman</surname><given-names>WA</given-names></name></person-group><article-title>P. somatostatin receptor scintigraphy with Indium 111-DTPA-D-Phe-1-Octreotide in Man: metabolism, Dosimetry and comparison with Iodine- 123-Tyr-3-Octreotide</article-title><source>J Nuclear Med</source><year>1992</year><volume>33</volume><issue>5</issue><fpage>652</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">1349039</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Krenning EP, Bakker WH, Kooij PPM, Breeman WA. P. somatostatin receptor scintigraphy with Indium 111-DTPA-D-Phe-1-Octreotide in Man: metabolism, Dosimetry and comparison with Iodine- 123-Tyr-3-Octreotide. J Nuclear Med. 1992;33(5):652&#8211;8.<pub-id pub-id-type="pmid">1349039</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Binnebeek</surname><given-names>S</given-names></name><name name-style="western"><surname>Vanbilloen</surname><given-names>B</given-names></name><name name-style="western"><surname>Baete</surname><given-names>K</given-names></name><name name-style="western"><surname>Terwinghe</surname><given-names>C</given-names></name><name name-style="western"><surname>Koole</surname><given-names>M</given-names></name><name name-style="western"><surname>Mottaghy</surname><given-names>FM</given-names></name><etal/></person-group><article-title>Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: a lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours</article-title><source>Eur Radiol</source><year>2016</year><volume>26</volume><issue>3</issue><fpage>900</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s00330-015-3882-1</pub-id><pub-id pub-id-type="pmid">26162577</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Van Binnebeek S, Vanbilloen B, Baete K, Terwinghe C, Koole M, Mottaghy FM, et al. Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: a lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours. Eur Radiol. 2016;26(3):900&#8211;9.<pub-id pub-id-type="pmid">26162577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00330-015-3882-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>I</given-names></name><name name-style="western"><surname>Paeng</surname><given-names>JC</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Shin</surname><given-names>CS</given-names></name><name name-style="western"><surname>Jang</surname><given-names>JY</given-names></name><name name-style="western"><surname>Cheon</surname><given-names>GJ</given-names></name><etal/></person-group><article-title>Comparison of diagnostic sensitivity and quantitative indices between 68Ga-DOTATOC PET/CT and 111In-Pentetreotide SPECT/CT in neuroendocrine tumors: a preliminary Report</article-title><source>Nucl Med Mol Imaging</source><year>2015</year><volume>49</volume><issue>4</issue><fpage>284</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1007/s13139-015-0356-y</pub-id><pub-id pub-id-type="pmid">26550047</pub-id><pub-id pub-id-type="pmcid">PMC4630328</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Lee I, Paeng JC, Lee SJ, Shin CS, Jang JY, Cheon GJ, et al. Comparison of diagnostic sensitivity and quantitative indices between 68Ga-DOTATOC PET/CT and 111In-Pentetreotide SPECT/CT in neuroendocrine tumors: a preliminary Report. Nucl Med Mol Imaging. 2015;49(4):284&#8211;90.<pub-id pub-id-type="pmid">26550047</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13139-015-0356-y</pub-id><pub-id pub-id-type="pmcid">PMC4630328</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadowski</surname><given-names>SM</given-names></name><name name-style="western"><surname>Neychev</surname><given-names>V</given-names></name><name name-style="western"><surname>Millo</surname><given-names>C</given-names></name><name name-style="western"><surname>Shih</surname><given-names>J</given-names></name><name name-style="western"><surname>Nilubol</surname><given-names>N</given-names></name><name name-style="western"><surname>Herscovitch</surname><given-names>P</given-names></name><etal/></person-group><article-title>Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites</article-title><source>J Clin Oncol</source><year>2016</year><volume>34</volume><issue>6</issue><fpage>588</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1200/JCO.2015.64.0987</pub-id><pub-id pub-id-type="pmid">26712231</pub-id><pub-id pub-id-type="pmcid">PMC4872030</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, et al. Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol. 2016;34(6):588&#8211;97.<pub-id pub-id-type="pmid">26712231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2015.64.0987</pub-id><pub-id pub-id-type="pmcid">PMC4872030</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sundin</surname><given-names>A</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>R</given-names></name><name name-style="western"><surname>Baudin</surname><given-names>E</given-names></name><name name-style="western"><surname>Cwikla</surname><given-names>JB</given-names></name><name name-style="western"><surname>Eriksson</surname><given-names>B</given-names></name><name name-style="western"><surname>Fanti</surname><given-names>S</given-names></name><etal/></person-group><article-title>ENETS Consensus guidelines for the standards of Care in Neuroendocrine tumors: Radiological, Nuclear Medicine and Hybrid Imaging</article-title><source>Neuroendocrinology</source><year>2017</year><volume>105</volume><issue>3</issue><fpage>212</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1159/000471879</pub-id><pub-id pub-id-type="pmid">28355596</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, et al. ENETS Consensus guidelines for the standards of Care in Neuroendocrine tumors: Radiological, Nuclear Medicine and Hybrid Imaging. Neuroendocrinology. 2017;105(3):212&#8211;44.<pub-id pub-id-type="pmid">28355596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000471879</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hicks</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Kwekkeboom</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Krenning</surname><given-names>E</given-names></name><name name-style="western"><surname>Bodei</surname><given-names>L</given-names></name><name name-style="western"><surname>Grozinsky-Glasberg</surname><given-names>S</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>R</given-names></name><etal/></person-group><article-title>ENETS Consensus guidelines for the standards of Care in Neuroendocrine neoplasms: peptide receptor Radionuclide Therapy with Radiolabelled somatostatin analogues</article-title><source>Neuroendocrinology</source><year>2017</year><volume>105</volume><issue>3</issue><fpage>295</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1159/000475526</pub-id><pub-id pub-id-type="pmid">28402980</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, et al. ENETS Consensus guidelines for the standards of Care in Neuroendocrine neoplasms: peptide receptor Radionuclide Therapy with Radiolabelled somatostatin analogues. Neuroendocrinology. 2017;105(3):295&#8211;309.<pub-id pub-id-type="pmid">28402980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000475526</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Virgolini</surname><given-names>I</given-names></name><name name-style="western"><surname>Ambrosini</surname><given-names>V</given-names></name><name name-style="western"><surname>Bomanji</surname><given-names>JB</given-names></name><name name-style="western"><surname>Baum</surname><given-names>RP</given-names></name><name name-style="western"><surname>Fanti</surname><given-names>S</given-names></name><name name-style="western"><surname>Gabriel</surname><given-names>M</given-names></name><etal/></person-group><article-title>Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA- conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2010</year><volume>37</volume><issue>10</issue><fpage>2004</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/s00259-010-1512-3</pub-id><pub-id pub-id-type="pmid">20596866</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA- conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37(10):2004&#8211;10.<pub-id pub-id-type="pmid">20596866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-010-1512-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Pajeau</surname><given-names>TS</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>WB</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>ELC</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>BE</given-names></name><name name-style="western"><surname>Welch</surname><given-names>MJ</given-names></name></person-group><article-title>In Vitro and in vivo evaluation of copper-64-Octreotide conjugates</article-title><source>J Nuclear Med</source><year>1995</year><volume>36</volume><issue>12</issue><fpage>2315</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">8523125</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Anderson CJ, Pajeau TS, Edwards WB, Sherman ELC, Rogers BE, Welch MJ. In Vitro and in vivo evaluation of copper-64-Octreotide conjugates. J Nuclear Med. 1995;36(12):2315&#8211;25.<pub-id pub-id-type="pmid">8523125</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfeifer</surname><given-names>A</given-names></name><name name-style="western"><surname>Knigge</surname><given-names>U</given-names></name><name name-style="western"><surname>Binderup</surname><given-names>T</given-names></name><name name-style="western"><surname>Mortensen</surname><given-names>J</given-names></name><name name-style="western"><surname>Oturai</surname><given-names>P</given-names></name><name name-style="western"><surname>Loft</surname><given-names>A</given-names></name><etal/></person-group><article-title>64Cu-DOTATATE PET for neuroendocrine tumors: a prospective head-to-Head comparison with 111In-DTPA-Octreotide in 112 patients</article-title><source>J Nucl Med</source><year>2015</year><volume>56</volume><issue>6</issue><fpage>847</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.2967/jnumed.115.156539</pub-id><pub-id pub-id-type="pmid">25952736</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Pfeifer A, Knigge U, Binderup T, Mortensen J, Oturai P, Loft A, et al. 64Cu-DOTATATE PET for neuroendocrine tumors: a prospective head-to-Head comparison with 111In-DTPA-Octreotide in 112 patients. J Nucl Med. 2015;56(6):847&#8211;54.<pub-id pub-id-type="pmid">25952736</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.115.156539</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfeifer</surname><given-names>A</given-names></name><name name-style="western"><surname>Knigge</surname><given-names>U</given-names></name><name name-style="western"><surname>Mortensen</surname><given-names>J</given-names></name><name name-style="western"><surname>Oturai</surname><given-names>P</given-names></name><name name-style="western"><surname>Berthelsen</surname><given-names>AK</given-names></name><name name-style="western"><surname>Loft</surname><given-names>A</given-names></name><etal/></person-group><article-title>Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study</article-title><source>J Nucl Med</source><year>2012</year><volume>53</volume><fpage>1207</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.2967/jnumed.111.101469</pub-id><pub-id pub-id-type="pmid">22782315</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Pfeifer A, Knigge U, Mortensen J, Oturai P, Berthelsen AK, Loft A, et al. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. J Nucl Med. 2012;53:1207&#8211;15.<pub-id pub-id-type="pmid">22782315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.111.101469</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnbeck</surname><given-names>CB</given-names></name><name name-style="western"><surname>Knigge</surname><given-names>U</given-names></name><name name-style="western"><surname>Loft</surname><given-names>A</given-names></name><name name-style="western"><surname>Berthelsen</surname><given-names>AK</given-names></name><name name-style="western"><surname>Mortensen</surname><given-names>J</given-names></name><name name-style="western"><surname>Oturai</surname><given-names>P</given-names></name><etal/></person-group><article-title>Head-to-Head comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors</article-title><source>J Nucl Med</source><year>2017</year><volume>58</volume><fpage>451</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.2967/jnumed.116.180430</pub-id><pub-id pub-id-type="pmid">27660147</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, et al. Head-to-Head comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors. J Nucl Med. 2017;58:451&#8211;7.<pub-id pub-id-type="pmid">27660147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.116.180430</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loft</surname><given-names>M</given-names></name><name name-style="western"><surname>Carlsen</surname><given-names>EA</given-names></name><name name-style="western"><surname>Johnbeck</surname><given-names>CB</given-names></name><name name-style="western"><surname>Johannesen</surname><given-names>HH</given-names></name><name name-style="western"><surname>Binderup</surname><given-names>T</given-names></name><name name-style="western"><surname>Pfeifer</surname><given-names>A</given-names></name><etal/></person-group><article-title>64Cu-DOTATATE PET in patients with neuroendocrine neoplasms: prospective, head-to-head comparison of imaging at 1 hour and 3 hours after injection</article-title><source>J Nucl Med</source><year>2020</year><volume>62</volume><issue>1</issue><fpage>62</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">32444370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.120.244509</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Loft M, Carlsen EA, Johnbeck CB, Johannesen HH, Binderup T, Pfeifer A, et al. 64Cu-DOTATATE PET in patients with neuroendocrine neoplasms: prospective, head-to-head comparison of imaging at 1 hour and 3 hours after injection. J Nucl Med. 2020;62(1):62&#8211;8.<pub-id pub-id-type="pmid">32444370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.120.244509</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlsen</surname><given-names>EA</given-names></name><name name-style="western"><surname>Johnbeck</surname><given-names>CB</given-names></name><name name-style="western"><surname>Binderup</surname><given-names>T</given-names></name><name name-style="western"><surname>Loft</surname><given-names>M</given-names></name><name name-style="western"><surname>Pfeifer</surname><given-names>A</given-names></name><name name-style="western"><surname>Mortensen</surname><given-names>J</given-names></name><etal/></person-group><article-title>64Cu-DOTATATE PET/CT and prediction of overall and progression-free survival in patients with neuroendocrine neoplasms</article-title><source>J Nucl Med</source><year>2020</year><volume>61</volume><issue>10</issue><fpage>1491</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.2967/jnumed.119.240143</pub-id><pub-id pub-id-type="pmid">32111685</pub-id><pub-id pub-id-type="pmcid">PMC7539650</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Carlsen EA, Johnbeck CB, Binderup T, Loft M, Pfeifer A, Mortensen J, et al. 64Cu-DOTATATE PET/CT and prediction of overall and progression-free survival in patients with neuroendocrine neoplasms. J Nucl Med. 2020;61(10):1491&#8211;7.<pub-id pub-id-type="pmid">32111685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.119.240143</pub-id><pub-id pub-id-type="pmcid">PMC7539650</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delpassand</surname><given-names>ES</given-names></name><name name-style="western"><surname>Ranganathan</surname><given-names>D</given-names></name><name name-style="western"><surname>Wagh</surname><given-names>N</given-names></name><name name-style="western"><surname>Shafie</surname><given-names>A</given-names></name><name name-style="western"><surname>Gaber</surname><given-names>A</given-names></name><name name-style="western"><surname>Abbasi</surname><given-names>A</given-names></name><etal/></person-group><article-title>64Cu-DOTATATE PET/CT for imaging patients with known or suspected somatostatin receptor-positive neuroendocrine tumors: results of the first U.S. prospective, reader-masked clinical trial</article-title><source>J Nucl Med</source><year>2020</year><volume>61</volume><issue>6</issue><fpage>890</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.2967/jnumed.119.236091</pub-id><pub-id pub-id-type="pmid">31924723</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Delpassand ES, Ranganathan D, Wagh N, Shafie A, Gaber A, Abbasi A, et al. 64Cu-DOTATATE PET/CT for imaging patients with known or suspected somatostatin receptor-positive neuroendocrine tumors: results of the first U.S. prospective, reader-masked clinical trial. J Nucl Med. 2020;61(6):890&#8211;6.<pub-id pub-id-type="pmid">31924723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.119.236091</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Fani M, Nicolas GP. 61Cu-Labeled Radiotracers: Alternative or Choice? Journal of Nuclear Medicine [Internet]. 2023;64(12):1855&#8211;7. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://jnm.snmjournals.org/lookup/doi/">http://jnm.snmjournals.org/lookup/doi/</ext-link>10.2967/jnumed.123.266171<pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.123.266171</pub-id><pub-id pub-id-type="pmcid">PMC10690116</pub-id><pub-id pub-id-type="pmid">37884329</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Fonseca AI, Alves VH, do Carmo SJC, Silva M, Hrynchak I, Alves F et al. Production of GMP-Compliant Clinical amounts of Copper-61 radiopharmaceuticals from Liquid targets. Pharmaceuticals. 2022;15(6).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ph15060723</pub-id><pub-id pub-id-type="pmcid">PMC9231368</pub-id><pub-id pub-id-type="pmid">35745642</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobs</surname><given-names>S</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>S</given-names></name></person-group><article-title>Intracellular trafficking of somatostatin receptors</article-title><source>Mol Cell Endocrinol</source><year>2008</year><volume>286</volume><issue>1&#8211;2</issue><fpage>58</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2007.10.005</pub-id><pub-id pub-id-type="pmid">18045773</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Jacobs S, Schulz S. Intracellular trafficking of somatostatin receptors. Mol Cell Endocrinol. 2008;286(1&#8211;2):58&#8211;62.<pub-id pub-id-type="pmid">18045773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mce.2007.10.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Eychenne R, Bouvry C, Bourgeois M, Loyer P, Benoist E, Lepareur N. Overview of Radiolabeled somatostatin analogs for Cancer Imaging and Therapy. Molecules. 2020;25(17).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules25174012</pub-id><pub-id pub-id-type="pmcid">PMC7504749</pub-id><pub-id pub-id-type="pmid">32887456</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Dewulf J, Flieswasser T, Delahaye T, Vangestel C, Miranda A, de Haard H et al. Site-specific 68Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models. EJNMMI Radiopharm Chem. 2023;8(1).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s41181-023-00194-3</pub-id><pub-id pub-id-type="pmcid">PMC10126183</pub-id><pub-id pub-id-type="pmid">37093350</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robu</surname><given-names>S</given-names></name><name name-style="western"><surname>Richter</surname><given-names>A</given-names></name><name name-style="western"><surname>Gosmann</surname><given-names>D</given-names></name><name name-style="western"><surname>Seidl</surname><given-names>C</given-names></name><name name-style="western"><surname>Leung</surname><given-names>D</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>W</given-names></name><etal/></person-group><article-title>Synthesis and preclinical evaluation of a 68Ga-Labeled adnectin, 68Ga-BMS-986192, as a PET Agent for Imaging PD-L1 expression</article-title><source>J Nucl Med</source><year>2021</year><volume>62</volume><issue>9</issue><fpage>1228</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.2967/jnumed.120.258384</pub-id><pub-id pub-id-type="pmid">33517324</pub-id><pub-id pub-id-type="pmcid">PMC8882891</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Robu S, Richter A, Gosmann D, Seidl C, Leung D, Hayes W, et al. Synthesis and preclinical evaluation of a 68Ga-Labeled adnectin, 68Ga-BMS-986192, as a PET Agent for Imaging PD-L1 expression. J Nucl Med. 2021;62(9):1228&#8211;34.<pub-id pub-id-type="pmid">33517324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.120.258384</pub-id><pub-id pub-id-type="pmcid">PMC8882891</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Houson HA, Tekin V, Lin W, Aluicio-Sarduy E, Engle JW, Lapi SE. PET imaging of the neurotensin targeting peptide NOTA-NT-20.3 using Cobalt-55, Copper-64 and Gallium-68. Pharmaceutics. 2022;14(12).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics14122724</pub-id><pub-id pub-id-type="pmcid">PMC9781609</pub-id><pub-id pub-id-type="pmid">36559218</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Domnanich KA, M&#252;ller C, Farkas R, Schmid RM, Ponsard B, Schibli R et al. 44Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations. EJNMMI Radiopharm Chem [Internet]. 2016;1(81):1&#8211;19. Available from: 10.1186/s41181-016-0013-5<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s41181-016-0013-5</pub-id><pub-id pub-id-type="pmcid">PMC5843811</pub-id><pub-id pub-id-type="pmid">29564385</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Xia Y, Zeng C, Zhao Y, Zhang X, Li Z, Chen Y. Comparative evaluation of 68Ga-labelled TATEs: the impact of chelators on imaging. EJNMMI Res. 2020;10(1).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13550-020-00620-6</pub-id><pub-id pub-id-type="pmcid">PMC7158967</pub-id><pub-id pub-id-type="pmid">32297029</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Pfeifer A, Johnbeck CB, Knigge U, Mortensen J, Oturai P, Loft A et al. Clinical PET imaging of neuroendocrine tumors using 64Cu-DOTA-Tyr3-octreotate. Journal of Nuclear Medicine [Internet]. 2013;54(supplement 2):1854. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://jnm.snmjournals.org/content/54/supplement_2/1854">https://jnm.snmjournals.org/content/54/supplement_2/1854</ext-link></mixed-citation></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Sui</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors</article-title><source>Theranostics</source><year>2022</year><volume>12</volume><issue>15</issue><fpage>6437</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.7150/thno.77219</pub-id><pub-id pub-id-type="pmid">36185603</pub-id><pub-id pub-id-type="pmcid">PMC9516233</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Jiang Y, Liu Q, Wang G, Sui H, Wang R, Wang J, et al. Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors. Theranostics. 2022;12(15):6437&#8211;45.<pub-id pub-id-type="pmid">36185603</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.77219</pub-id><pub-id pub-id-type="pmcid">PMC9516233</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clement</surname><given-names>D</given-names></name><name name-style="western"><surname>Navalkissoor</surname><given-names>S</given-names></name><name name-style="western"><surname>Srirajaskanthan</surname><given-names>R</given-names></name><name name-style="western"><surname>Courbon</surname><given-names>F</given-names></name><name name-style="western"><surname>Dierickx</surname><given-names>L</given-names></name><name name-style="western"><surname>Eccles</surname><given-names>A</given-names></name><etal/></person-group><article-title>Efficacy and safety of 177LuDOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2022</year><volume>49</volume><issue>10</issue><fpage>3529</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1007/s00259-022-05771-3</pub-id><pub-id pub-id-type="pmid">35389069</pub-id><pub-id pub-id-type="pmcid">PMC9308585</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Clement D, Navalkissoor S, Srirajaskanthan R, Courbon F, Dierickx L, Eccles A, et al. Efficacy and safety of 177LuDOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study. Eur J Nucl Med Mol Imaging. 2022;49(10):3529&#8211;37.<pub-id pub-id-type="pmid">35389069</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-022-05771-3</pub-id><pub-id pub-id-type="pmcid">PMC9308585</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Yadav MP, Ballal S, Bal C, Sahoo RK, Damle NA, Tripathi M et al. Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients. Clin Nucl Med [Internet]. 2020;45(1):19&#8211;31. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://journals.lww.com/nuclearmed/fulltext/2020/01000/efficacy_and_safety_of_177lu_psma_617_radioligand.4.aspx">https://journals.lww.com/nuclearmed/fulltext/2020/01000/efficacy_and_safety_of_177lu_psma_617_radioligand.4.aspx</ext-link><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/RLU.0000000000002833</pub-id><pub-id pub-id-type="pmid">31789908</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Demirkol MO, Esen B, Seymen H, &#350;en M, U&#231;ar B, Kurtuldu S et al. Radioligand Therapy With 177Lu-PSMA-I&amp;T in Patients With Metastatic Prostate Cancer: Oncological Outcomes and Toxicity Profile. Clin Nucl Med [Internet]. 2023;48(12). Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://journals.lww.com/nuclearmed/fulltext/2023/12000/radioligand_therapy_with_177lu_psma_i_t_in.40.aspx">https://journals.lww.com/nuclearmed/fulltext/2023/12000/radioligand_therapy_with_177lu_psma_i_t_in.40.aspx</ext-link><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/RLU.0000000000004901</pub-id><pub-id pub-id-type="pmid">37844332</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>DR</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><etal/></person-group><article-title>microPET Imaging of Glioma Integrin &#945;v&#946;3 expression using 64Cu-Labeled tetrameric RGD peptide</article-title><source>J Nuclear Med</source><year>2005</year><volume>46</volume><issue>10</issue><fpage>1707</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">16204722</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher DR, Liu S, et al. microPET Imaging of Glioma Integrin &#945;v&#946;3 expression using 64Cu-Labeled tetrameric RGD peptide. J Nuclear Med. 2005;46(10):1707&#8211;18.<pub-id pub-id-type="pmid">16204722</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McQuade</surname><given-names>P</given-names></name><name name-style="western"><surname>Miao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>J</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>TP</given-names></name><name name-style="western"><surname>Welch</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>JS</given-names></name></person-group><article-title>Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH</article-title><source>J Med Chem</source><year>2005</year><volume>48</volume><issue>8</issue><fpage>2985</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1021/jm0490282</pub-id><pub-id pub-id-type="pmid">15828837</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">McQuade P, Miao Y, Yoo J, Quinn TP, Welch MJ, Lewis JS. Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH. J Med Chem. 2005;48(8):2985&#8211;92.<pub-id pub-id-type="pmid">15828837</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jm0490282</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garrison</surname><given-names>JC</given-names></name><name name-style="western"><surname>Rold</surname><given-names>TL</given-names></name><name name-style="western"><surname>Sieckman</surname><given-names>GL</given-names></name><name name-style="western"><surname>Figueroa</surname><given-names>SD</given-names></name><name name-style="western"><surname>Volkert</surname><given-names>WA</given-names></name><name name-style="western"><surname>Jurisson</surname><given-names>SS</given-names></name><etal/></person-group><article-title>In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems</article-title><source>J Nucl Med</source><year>2007</year><volume>48</volume><issue>8</issue><fpage>1327</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.2967/jnumed.107.039487</pub-id><pub-id pub-id-type="pmid">17631556</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Garrison JC, Rold TL, Sieckman GL, Figueroa SD, Volkert WA, Jurisson SS, et al. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med. 2007;48(8):1327&#8211;37.<pub-id pub-id-type="pmid">17631556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.107.039487</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boswell</surname><given-names>CA</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Niu</surname><given-names>W</given-names></name><name name-style="western"><surname>Weisman</surname><given-names>GR</given-names></name><name name-style="western"><surname>Wong</surname><given-names>EH</given-names></name><name name-style="western"><surname>Rheingold</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Comparative in vivo Stability of Copper-64-Labeled Cross-bridged and Conventional Tetraazamacrocyclic complexes</article-title><source>J Nucl Med</source><year>2004</year><volume>47</volume><fpage>1465</fpage><lpage>74</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jm030383m</pub-id><pub-id pub-id-type="pmid">14998334</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Boswell CA, Sun X, Niu W, Weisman GR, Wong EH, Rheingold AL, et al. Comparative in vivo Stability of Copper-64-Labeled Cross-bridged and Conventional Tetraazamacrocyclic complexes. J Nucl Med. 2004;47:1465&#8211;74.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jm030383m</pub-id><pub-id pub-id-type="pmid">14998334</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanaoka</surname><given-names>H</given-names></name><name name-style="western"><surname>Tominaga</surname><given-names>H</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>K</given-names></name><name name-style="western"><surname>Paudyal</surname><given-names>P</given-names></name><name name-style="western"><surname>Iida</surname><given-names>Y</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>S</given-names></name><etal/></person-group><article-title>Evaluation of 64Cu-labeled DOTA-d-Phe1-Tyr 3-octreotide (64Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors</article-title><source>Ann Nucl Med</source><year>2009</year><volume>23</volume><issue>6</issue><fpage>559</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1007/s12149-009-0274-0</pub-id><pub-id pub-id-type="pmid">19504168</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Hanaoka H, Tominaga H, Yamada K, Paudyal P, Iida Y, Watanabe S, et al. Evaluation of 64Cu-labeled DOTA-d-Phe1-Tyr 3-octreotide (64Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors. Ann Nucl Med. 2009;23(6):559&#8211;67.<pub-id pub-id-type="pmid">19504168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12149-009-0274-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>JS</given-names></name><name name-style="western"><surname>Laforest</surname><given-names>R</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>M</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>CJ</given-names></name></person-group><article-title>Comparative dosimetry of Copper-64 and Yttrium-90-Labeled somatostatin analogs in a tumor-bearing rat model</article-title><source>Cancer Biotherapy Radiopharmaceuticals</source><year>2000</year><volume>15</volume><issue>6</issue><fpage>593</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1089/cbr.2000.15.593</pub-id><pub-id pub-id-type="pmid">11190491</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Lewis JS, Laforest R, Lewis M, Anderson CJ. Comparative dosimetry of Copper-64 and Yttrium-90-Labeled somatostatin analogs in a tumor-bearing rat model. Cancer Biotherapy Radiopharmaceuticals. 2000;15(6):593&#8211;604.<pub-id pub-id-type="pmid">11190491</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/cbr.2000.15.593</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paterson</surname><given-names>BM</given-names></name><name name-style="western"><surname>Roselt</surname><given-names>P</given-names></name><name name-style="western"><surname>Denoyer</surname><given-names>D</given-names></name><name name-style="western"><surname>Cullinane</surname><given-names>C</given-names></name><name name-style="western"><surname>Binns</surname><given-names>D</given-names></name><name name-style="western"><surname>Noonan</surname><given-names>W</given-names></name><etal/></person-group><article-title>PET imaging of tumours with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate</article-title><source>Dalton Trans</source><year>2014</year><volume>43</volume><issue>3</issue><fpage>1386</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1039/C3DT52647J</pub-id><pub-id pub-id-type="pmid">24202174</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Paterson BM, Roselt P, Denoyer D, Cullinane C, Binns D, Noonan W, et al. PET imaging of tumours with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate. Dalton Trans. 2014;43(3):1386&#8211;96.<pub-id pub-id-type="pmid">24202174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c3dt52647j</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooper</surname><given-names>MS</given-names></name><name name-style="western"><surname>Ma</surname><given-names>MT</given-names></name><name name-style="western"><surname>Sunassee</surname><given-names>K</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>KP</given-names></name><name name-style="western"><surname>Williams</surname><given-names>JD</given-names></name><name name-style="western"><surname>Paul</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Comparison of 64Cu-Complexing Bifunctional Chelators for Radioimmunoconjugation: labeling efficiency, specific activity, and in Vitro/in vivo Stability</article-title><source>Bioconjug Chem</source><year>2012</year><volume>23</volume><fpage>1029</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1021/bc300037w</pub-id><pub-id pub-id-type="pmid">22471317</pub-id><pub-id pub-id-type="pmcid">PMC4756438</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Cooper MS, Ma MT, Sunassee K, Shaw KP, Williams JD, Paul RL, et al. Comparison of 64Cu-Complexing Bifunctional Chelators for Radioimmunoconjugation: labeling efficiency, specific activity, and in Vitro/in vivo Stability. Bioconjug Chem. 2012;23:1029&#8211;39.<pub-id pub-id-type="pmid">22471317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/bc300037w</pub-id><pub-id pub-id-type="pmcid">PMC4756438</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dearling</surname><given-names>JLJ</given-names></name><name name-style="western"><surname>Voss</surname><given-names>SD</given-names></name><name name-style="western"><surname>Dunning</surname><given-names>P</given-names></name><name name-style="western"><surname>Snay</surname><given-names>E</given-names></name><name name-style="western"><surname>Fahey</surname><given-names>F</given-names></name><name name-style="western"><surname>Smith</surname><given-names>SV</given-names></name><etal/></person-group><article-title>Imaging cancer using PET - the effect of the bifunctional chelator on the biodistribution of a 64Cu-labeled antibody</article-title><source>Nucl Med Biol</source><year>2011</year><volume>38</volume><issue>1</issue><fpage>29</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.nucmedbio.2010.07.003</pub-id><pub-id pub-id-type="pmid">21220127</pub-id><pub-id pub-id-type="pmcid">PMC3032412</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Dearling JLJ, Voss SD, Dunning P, Snay E, Fahey F, Smith SV, et al. Imaging cancer using PET - the effect of the bifunctional chelator on the biodistribution of a 64Cu-labeled antibody. Nucl Med Biol. 2011;38(1):29&#8211;38.<pub-id pub-id-type="pmid">21220127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nucmedbio.2010.07.003</pub-id><pub-id pub-id-type="pmcid">PMC3032412</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">Prasanphanich AF, Nanda PK, Rold TL, Ma L, Lewis MR, Garrison JC et al. [64Cu-NOTA-8-Aoc-BBN(7&#8211;14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proceedings of the National Academy of Sciences USA [Internet]. 2007;104(30):12462&#8211;7. Available from: www.pnas.orgcgidoi10.1073pnas.0705347104.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0705347104</pub-id><pub-id pub-id-type="pmcid">PMC1914305</pub-id><pub-id pub-id-type="pmid">17626788</pub-id></mixed-citation></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prasanphanich</surname><given-names>AF</given-names></name><name name-style="western"><surname>Retzloff</surname><given-names>L</given-names></name><name name-style="western"><surname>Lane</surname><given-names>SR</given-names></name><name name-style="western"><surname>Nanda</surname><given-names>PK</given-names></name><name name-style="western"><surname>Sieckman</surname><given-names>GL</given-names></name><name name-style="western"><surname>Rold</surname><given-names>TL</given-names></name><etal/></person-group><article-title>In vitro and in vivo analysis of [64Cu-NO2A-8-Aoc-BBN(7&#8211;14)NH2]: a site-directed radiopharmaceutical for positron-emission tomography imaging of T-47D human breast cancer tumors</article-title><source>Nucl Med Biol</source><year>2009</year><volume>36</volume><issue>2</issue><fpage>171</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.nucmedbio.2008.11.005</pub-id><pub-id pub-id-type="pmid">19217529</pub-id><pub-id pub-id-type="pmcid">PMC2756974</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Prasanphanich AF, Retzloff L, Lane SR, Nanda PK, Sieckman GL, Rold TL, et al. In vitro and in vivo analysis of [64Cu-NO2A-8-Aoc-BBN(7&#8211;14)NH2]: a site-directed radiopharmaceutical for positron-emission tomography imaging of T-47D human breast cancer tumors. Nucl Med Biol. 2009;36(2):171&#8211;81.<pub-id pub-id-type="pmid">19217529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nucmedbio.2008.11.005</pub-id><pub-id pub-id-type="pmcid">PMC2756974</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reubi</surname><given-names>JC</given-names></name><name name-style="western"><surname>Sch&#228;r</surname><given-names>JC</given-names></name><name name-style="western"><surname>Waser</surname><given-names>B</given-names></name><name name-style="western"><surname>Wenger</surname><given-names>S</given-names></name><name name-style="western"><surname>Heppeler</surname><given-names>A</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Affinity profiles for human somatostatin receptor subtypes SST1&#8211;SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use</article-title><source>Eur J Nucl Med</source><year>2000</year><volume>27</volume><issue>3</issue><fpage>273</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1007/s002590050034</pub-id><pub-id pub-id-type="pmid">10774879</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Reubi JC, Sch&#228;r JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1&#8211;SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27(3):273&#8211;82.<pub-id pub-id-type="pmid">10774879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002590050034</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raheem</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Salih</surname><given-names>AK</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>MD</given-names></name><name name-style="western"><surname>Sharpe</surname><given-names>JC</given-names></name><name name-style="western"><surname>Toosi</surname><given-names>BM</given-names></name><name name-style="western"><surname>Price</surname><given-names>EW</given-names></name></person-group><article-title>A systematic investigation into the influence of net charge on the Biological distribution of radiometalated peptides using [68Ga]Ga-DOTA-TATE derivatives</article-title><source>Bioconjug Chem</source><year>2023</year><volume>34</volume><issue>3</issue><fpage>549</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.3c00007</pub-id><pub-id pub-id-type="pmid">36800496</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Raheem SJ, Salih AK, Garcia MD, Sharpe JC, Toosi BM, Price EW. A systematic investigation into the influence of net charge on the Biological distribution of radiometalated peptides using [68Ga]Ga-DOTA-TATE derivatives. Bioconjug Chem. 2023;34(3):549&#8211;61.<pub-id pub-id-type="pmid">36800496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.bioconjchem.3c00007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="other">Mitran B, Thisgaard H, Rinne S, Dam JH, Azami F, Tolmachev V et al. Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26. Sci Rep. 2019;9(1).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-019-52914-y</pub-id><pub-id pub-id-type="pmcid">PMC6863848</pub-id><pub-id pub-id-type="pmid">31745219</pub-id></mixed-citation></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geraldes</surname><given-names>CFGC</given-names></name><name name-style="western"><surname>Marques</surname><given-names>MPM</given-names></name><name name-style="western"><surname>De Castro</surname><given-names>B</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>E</given-names></name></person-group><article-title>Study of copper(II) Polyazamacrocyclic Complexes by electronic absorption spectrophotometry and EPR spectroscopy</article-title><source>Eur J Inorg Chem</source><year>2000</year><volume>2000</volume><issue>3</issue><fpage>559</fpage><lpage>68</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1099-0682(200003)2000:3&amp;#x0003c;559::AID-EJIC559&amp;#x0003e;3.0.CO;2-J</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Geraldes CFGC, Marques MPM, De Castro B, Pereira E. Study of copper(II) Polyazamacrocyclic Complexes by electronic absorption spectrophotometry and EPR spectroscopy. Eur J Inorg Chem. 2000;2000(3):559&#8211;68.</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>SV</given-names></name></person-group><article-title>Molecular imaging with copper-64</article-title><source>J Inorg Biochem</source><year>2004</year><volume>98</volume><fpage>1874</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2004.06.009</pub-id><pub-id pub-id-type="pmid">15522415</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Smith SV. Molecular imaging with copper-64. J Inorg Biochem. 2004;98:1874&#8211;901.<pub-id pub-id-type="pmid">15522415</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jinorgbio.2004.06.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kub&#237;&#269;ek</surname><given-names>V</given-names></name><name name-style="western"><surname>Havl&#237;&#269;kov&#225;</surname><given-names>J</given-names></name><name name-style="western"><surname>Kotek</surname><given-names>J</given-names></name><name name-style="western"><surname>Tircs&#243;</surname><given-names>G</given-names></name><name name-style="western"><surname>Hermann</surname><given-names>P</given-names></name><name name-style="western"><surname>T&#243;th</surname><given-names>&#201;</given-names></name><etal/></person-group><article-title>Gallium(III) complexes of DOTA and DOTA-Monoamide: kinetic and thermodynamic studies</article-title><source>Inorg Chem</source><year>2010</year><volume>49</volume><issue>23</issue><fpage>10960</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1021/ic101378s</pub-id><pub-id pub-id-type="pmid">21047078</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Kub&#237;&#269;ek V, Havl&#237;&#269;kov&#225; J, Kotek J, Tircs&#243; G, Hermann P, T&#243;th &#201;, et al. Gallium(III) complexes of DOTA and DOTA-Monoamide: kinetic and thermodynamic studies. Inorg Chem. 2010;49(23):10960&#8211;9.<pub-id pub-id-type="pmid">21047078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ic101378s</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Froidevaux</surname><given-names>S</given-names></name><name name-style="western"><surname>Eberle</surname><given-names>AN</given-names></name><name name-style="western"><surname>Christe</surname><given-names>M</given-names></name><name name-style="western"><surname>Sumanovski</surname><given-names>L</given-names></name><name name-style="western"><surname>Heppeler</surname><given-names>A</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model</article-title><source>Int J Cancer</source><year>2002</year><volume>98</volume><issue>6</issue><fpage>930</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1002/ijc.10295</pub-id><pub-id pub-id-type="pmid">11948475</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Froidevaux S, Eberle AN, Christe M, Sumanovski L, Heppeler A, Schmitt JS, et al. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model. Int J Cancer. 2002;98(6):930&#8211;7.<pub-id pub-id-type="pmid">11948475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.10295</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="other">M&#252;ller C, Vermeulen C, Johnston K, K&#246;ster U, Schmid R, T&#252;rler A et al. Preclinical in vivo application of 152&#160;Tb-DOTANOC: a radiolanthanide for PET imaging. EJNMMI Res. 2016;6(1).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13550-016-0189-4</pub-id><pub-id pub-id-type="pmcid">PMC4842197</pub-id><pub-id pub-id-type="pmid">27108447</pub-id></mixed-citation></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones-Wilson</surname><given-names>TM</given-names></name><name name-style="western"><surname>Deal</surname><given-names>KA</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Mccarthy</surname><given-names>DW</given-names></name><name name-style="western"><surname>Kovacs</surname><given-names>Z</given-names></name><name name-style="western"><surname>Motekaitis</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>The in vivo behavior of copper-64-Labeled Azamacrocyclic complexes</article-title><source>Nucl Med Biol</source><year>1998</year><volume>25</volume><fpage>523</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/S0969-8051(98)00017-1</pub-id><pub-id pub-id-type="pmid">9751418</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Jones-Wilson TM, Deal KA, Anderson CJ, Mccarthy DW, Kovacs Z, Motekaitis RJ, et al. The in vivo behavior of copper-64-Labeled Azamacrocyclic complexes. Nucl Med Biol. 1998;25:523&#8211;39.<pub-id pub-id-type="pmid">9751418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0969-8051(98)00017-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="other">Fonseca AI, Alves VH, do Carmo SJC, Alves F, Abrunhosa AJ. Copper-61 from liquid targets: optimized purification for GMP labelling. Nucl Med Biol. 2021;96&#8211;7.</mixed-citation></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>do Carmo</surname><given-names>SJC</given-names></name><name name-style="western"><surname>Alves</surname><given-names>VH</given-names></name><name name-style="western"><surname>Alves</surname><given-names>F</given-names></name><name name-style="western"><surname>Abrunhosa</surname><given-names>AJ</given-names></name></person-group><article-title>Fast and cost-effective cyclotron production of 61Cu using a natZn liquid target: an opportunity for radiopharmaceutical production and R&amp;D</article-title><source>Dalton Trans</source><year>2017</year><volume>46</volume><fpage>14556</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1039/C7DT01836C</pub-id><pub-id pub-id-type="pmid">28702664</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">do Carmo SJC, Alves VH, Alves F, Abrunhosa AJ. Fast and cost-effective cyclotron production of 61Cu using a natZn liquid target: an opportunity for radiopharmaceutical production and R&amp;D. Dalton Trans. 2017;46:14556&#8211;60.<pub-id pub-id-type="pmid">28702664</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c7dt01836c</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alves</surname><given-names>VH</given-names></name><name name-style="western"><surname>do Carmo</surname><given-names>SJC</given-names></name><name name-style="western"><surname>Alves</surname><given-names>F</given-names></name><name name-style="western"><surname>Abrunhosa</surname><given-names>AJ</given-names></name></person-group><article-title>Automated purification of Radiometals produced by liquid targets</article-title><source>Instruments</source><year>2018</year><volume>2</volume><issue>17</issue><fpage>1</fpage><lpage>9</lpage></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Alves VH, do Carmo SJC, Alves F, Abrunhosa AJ. Automated purification of Radiometals produced by liquid targets. Instruments. 2018;2(17):1&#8211;9.</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alves</surname><given-names>F</given-names></name><name name-style="western"><surname>Alves</surname><given-names>VH</given-names></name><name name-style="western"><surname>Carmo</surname><given-names>SJC</given-names></name><name name-style="western"><surname>Neves</surname><given-names>A</given-names></name><name name-style="western"><surname>Silva</surname><given-names>M</given-names></name><name name-style="western"><surname>Abrunhosa</surname><given-names>AJ</given-names></name></person-group><article-title>Production of copper-64 and gallium-68 with a medical cyclotron using liquid targets</article-title><source>Mod Phys Lett A</source><year>2017</year><volume>32</volume><issue>17</issue><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1142/S0217732317400132</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Alves F, Alves VH, Carmo SJC, Neves A, Silva M, Abrunhosa AJ. Production of copper-64 and gallium-68 with a medical cyclotron using liquid targets. Mod Phys Lett A. 2017;32(17):1&#8211;21.</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><mixed-citation publication-type="other">Fonseca AI, Alves VH, Hrynchak I, Alves F, Abrunhosa AJ. Fully Automated Production of [68Ga]GaFAPI-46 with Gallium-68 from Cyclotron Using Liquid Targets. Int J Mol Sci [Internet]. 2023;24(20):15101. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.mdpi.com/1422-0067/24/20/15101">https://www.mdpi.com/1422-0067/24/20/15101</ext-link><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms242015101</pub-id><pub-id pub-id-type="pmcid">PMC10606668</pub-id><pub-id pub-id-type="pmid">37894781</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>